

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

BB

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07H 21/02, C12P 21/06, C07K 1/00, 14/00	A1	(11) International Publication Number: WO 98/42725 (43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/US98/05629 (22) International Filing Date: 20 March 1998 (20.03.98) (30) Priority Data: 60/044,425 21 March 1997 (21.03.97) US (71) Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT [US/US]; 171 Ashley Avenue, Charleston, SC 29425 (US). (72) Inventors: VOURNAKIS, John, N.; 19 Menotti Street, Charleston, SC 29401 (US). SETH, Arun, K.; 923 Drysdale Drive, Mississauga, Ontario L5V 1X6 (CA). PAPAS, Takis, S.; 84 C Bull Street, Charleston, SC 29401 (US). (74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF BREAST CANCER (57) Abstract <p>The present invention relates to a novel gene, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell lines, and in several normal tissues. The full length cDNA encodes a protein of 339 amino acids. Antibodies to the gene product were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. Di12 was also present in IDC-breast cancer patient sera, and its expression level increased markedly if IDC was accompanied by lymph node or distal metastases. As IDC constitutes ~70 % of breast cancers seen clinically, the level of Di12 expression is useful for diseases diagnosis predicting disease progression and monitoring a therapeutic treatment.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**METHODS AND COMPOSITIONS FOR
DIAGNOSIS AND TREATMENT OF BREAST CANCER**

1. INTRODUCTION

5 The present invention relates to the discovery,
identification and characterization of nucleotides that
encode Dil2, a protein that is overexpressed in breast cancer
tissue. The invention encompasses Dil2 nucleotides, host
cell expression systems, Dil2 proteins, fusion proteins,
10 polypeptides and peptides, antibodies to the gene product,
transgenic animals that express an Dil2 transgene, or
recombinant knock-out animals that do not express the Dil2,
and other compounds that modulate Dil2 gene expression or
Dil2 activity that can be used for diagnosis, disease
15 monitoring, drug screening, and/or the treatment of cancer
disorders, including but not limited to breast cancer.

2. BACKGROUND

20 Cancer is characterized primarily by an increase in the
number of abnormal cells derived from a given normal tissue,
invasion of adjacent tissues by these abnormal cells, and
lymphatic or blood-borne spread of malignant cells to
regional lymph nodes and to distant sites (metastasis).
Clinical data and molecular biologic studies indicate that
25 cancer is a multistep process that begins with minor
preneoplastic changes, which may under certain conditions
progress to neoplasia.

Pre-malignant abnormal cell growth is exemplified by
hyperplasia, metaplasia, or most particularly, dysplasia (for
30 review of such abnormal growth conditions, see Robbins &
Angell, 1976, *Basic Pathology*, 2d Ed., W.B. Saunders Co.,
Philadelphia, pp. 68-79.) The neoplastic lesion may evolve
clonally and develop an increasing capacity for growth,
metastasis, and heterogeneity, especially under conditions in
35 which the neoplastic cells escape the host's immune
surveillance (Roitt, I., Brostoff, J and Kale, D., 1993,
Immunology, 3rd ed., Mosby, St. Louis, pps. 17.1-17.12).

Breast cancer is the most common form of malignancy in women. One in nine women in North America will develop breast cancer and about 30% of them will ultimately die from the disease (Boring et al., 1993, *Cancer Statistics*, CA-A
5 *Journal for Physicians*, 43:7-26). The American Cancer Society estimated that in 1992 180,000 American women were diagnosed with breast cancer and 46,000 succumbed to the disease (Niederhuber, J.E. ed. *Current Therapy in Oncology* B.C. Decker, Mosby, 1993). A disturbing fact is the
10 observation that breast cancer has been increasing at a rate of 3 percent per year since 1980 (Niederhuber, J.E., ed. *Current Therapy in Oncology*, B.C. Decker, Mosby, 1993).

The natural history of breast cancer is characterized by a long duration and marked heterogeneity within and among
15 patients. Breast cancer is among the more slow-growing tumors, and the preclinical period before diagnosis and the clinical phases after initial treatment and even after the appearance of metastasis are measured in years and decades. Nevertheless, some patients have aggressive forms of the
20 disease and do poorly. Other patients have such indolent forms of the disease that it is difficult to demonstrate that therapy has any effect on survival. During the long clinical phase, there is ample opportunity for clonal mutation and evolution, and it seems probable that individual patients may
25 have multiple tumor clones, each with its own growth rate, propensity to metastasize, and sensitivity to drugs.

In both Europe and North America, early detection campaigns based on mass screening programs have been introduced in an effort to reduce mortality rates.
30 Widespread use of these procedures has resulted in an increased frequency of detection of breast cancer, which in turn has contributed to a greater number of women with early stage disease (Harris et al., 1993, *Cancer: Principles and Practice of Oncology*, eds. De Vita, V.T., Hellman, S., &
35 Rosenberg, S.A. (J.B. Lippincott, Philadelphia), 4th Ed., pp. 1264-1332). Given the high degree of morphological heterogeneity of most breast cancers, it is at present still

difficult to assess appropriate therapy and risk of recurrence for the majority of women who present with early stage disease. The currently available criteria affecting prognosis are tumor size and grade, lymph node status, DNA
5 ploidy and mitotic index, lymphovascular invasion, as well as estrogen receptor status (Harris et al., 1993, *Cancer: Principles and Practice of Oncology*, eds. De Vita, V.T., Hellman, S., & Rosenberg, S.A., J.B. Lippincott, Philadelphia, 4th Ed., pp. 1264-1332). These multiple
10 parameters remain poorly correlated with the molecular events associated with a multi-step progression of malignancy, e.g., it has been recently well defined for colorectal cancers (Vogelstein et al., 1993, *Trends in Genetics*, 9:138-141; Kinzler et al., 1996, *Cell*, 87:159-170).
15 The recent discoveries that individuals with BRCA1 and BRCA2 mutations have a predisposition to breast cancer may now facilitate the detection of an early onset type disease for hereditary breast cancer (Easton et al., 1993, *Cancer Surv*, 18:95-1131; Miki et al., 1994, *Science*, 266:66-71;
20 Tavtigian et al., 1994, *Nature Gen*, 12:333-337). The incidence of these cases however, is just 5-10% of all known breast cancers (Easton et al., 1993, *Cancer Surv*, 18:95-1131; Miki et al., 1994, *Science*, 266:66-71; Tavtigian et al., 1994, *Nature Gen*, 12:333-337). Thus, early and late stage
25 specific tumor markers are desperately needed for more than 90% of sporadic forms of breast malignancies.

Tumor suppressor genes and oncogenes play critical roles in the development of malignancies. Amplification and activation of several oncogenes in primary breast tissues
30 such as c-erb-b2 (HER-2/neu), c-MYC and INT2, have been previously implicated and subsequently evaluated for their prognostic potential (Allred et al., 1990, *Proc Am Soc Clin Oncol*, 9:23; Berns et al., 1992, *Cancer Res.*, 52:1107-1113). Molecular factors such as growth factor receptors and hormone
35 induced genes have also been investigated (Sainsbury et al., 1987, *Lancet*, 1:1398-1402; Iwase et al., 1994, *Breast Cancer Res Treat*, 33:83-88). Unfortunately, the expression of these

genes is often limited to a small percentage of breast carcinomas only, and their predictive prognostic value remains unclear. The need for markers which would discriminate biological differences between primary and
5 metastatic breast tumors and provide early diagnosis remains pressing. Such factors would assist in identifying individuals at risk for aggressive disease, and aid therapeutic decisions.

10

3. SUMMARY OF THE INVENTION

The present invention relates to the identification of novel genes whose expression pattern is upregulated in breast cancer tissues and cell lines, and the use of such genes and gene products as targets for diagnosis, drug screening and
15 therapies.

In particular, the compositions of the present invention include nucleic acid molecules that encode the novel Di12 protein, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring
20 variants which encode novel Di12 gene products. The compositions of the present invention additionally include cloning vectors, including expression vectors, containing the nucleic acid molecules of the invention and hosts which contain such nucleic acid molecules. The compositions of the
25 present invention also encompass the Di12 gene products, fusion proteins, and antibodies directed against such Di12 gene products or conserved variants or fragments thereof.

The nucleic acid sequence of the human Di12 gene (SEQ ID NO:1) is provided. The Di12 gene produces a transcript of
30 approximately 1.35 kb and encodes a protein of 339 amino acids with a molecular weight of approximately 35 kD. Transcripts were detected in several breast cancer cell lines, as well as various normal tissues, including lung, kidney, pancreas and heart. The amino acid sequence of the
35 predicted full length Di12 gene product does not contain a recognizable signal sequence, indicating that the Di12 gene product is an intracellular protein.

The present invention further relates to methods for the diagnostic evaluation and prognosis of breast cancer. For example, nucleic acid molecules of the invention can be used as diagnostic hybridization probes or as primers for
5 diagnostic PCR analysis for detection of abnormal expression of the D112 gene.

Antibodies to D112 gene product of the invention can be used in a diagnostic test to detect the presence of D112 gene product in body fluids. In specific embodiments, measurement
10 of serum or plasma D112 gene product levels can be made to detect or stage breast cancer, especially infiltrative ductal carcinoma.

The present invention also relates to methods for the identification of subjects having a predisposition to breast
15 cancer. For example, nucleic acid molecules of the invention can be used as diagnostic hybridization probes or as primers for diagnostic PCR analysis for the identification of D112 gene mutations, allelic variations and regulatory defects in the D112 gene.

20 Further, methods and compositions are presented for the treatment of breast cancer. Such methods and compositions are capable of modulating the level of D112 gene expression and/or the level of D112 gene product activity.

Still further, the present invention relates to methods
25 for the use of the D112 gene and/or D112 gene products for the identification of compounds which modulate D112 gene expression and/or the activity of D112 gene products. Such compounds can be used as agents to prevent and/or treat breast cancer. Such compounds can also be used to palliate
30 the symptoms of the disease, and control the metastatic potential of breast cancer.

4. BRIEF DESCRIPTION OF THE FIGURES

Fig. 1A-B. Figure 1A. The predicted amino acid
35 sequence of D112 protein. The 12 N-terminal amino acids used for generating antibodies are italicized, N-glycosylation sites are boxed, PKC sites are bold, and CKU sites are

underlined. Figure 1B. The complementary DNA (cDNA) sequence encoding Di12. The initiation codon is underlined and the termination codon is boxed.

Fig. 2. Immunoprecipitation of Di12 expressed using an *in vitro* expression system. ³⁵S-Met labeled Di12 protein was synthesized *in vitro* using the TnT kit (Promega) and immunoprecipitated with Di12 specific antibodies (Lanes 3 and 4) or preimmune serum (Lane 2). Lane 1 contains *in vitro* translated Di12 protein.

10 Fig. 3A-G. Expression of Di12 in breast cancer cell lines and normal tissues. RNA from breast cancer cell lines (Fig. 3A and 3C) and normal human (Fig. 3E) and rat tissues (Fig. 3F) were analyzed by Northern hybridization with a Di12 probe. 1.35 kb Di12 specific RNA is indicated by arrows in
15 each panel. Ethidium bromide stained agarose gels before blotting are shown below each autoradiogram (Fig. 3B, 3D and 3G) except for normal human tissues where a poly-A blot from Clontech was used. Names of cell lines and tissues are indicated above each lane.

20 Fig. 4A-H: Immunohistochemical analysis of Di12 expression

Fig. 4A-D. Analysis of paraffin embedded cell preparations from breast cancer cell lines using Di12 antibody: BT-483, Fig. 4A (150x), Fig. 4D (1000x). Hs578T,
25 Fig. 4C (150x). Fig. 4B is a negative control for A. BT-483 cells probed with rat immunoglobulins show only hematoxylin stain, Fig. 4B (150x). Interestingly the appearance of BT 483 (origin: infiltrative ductal carcinoma) cell architecture is tubular papillary-like, although without stromal support.

30 Fig. 4E-H. Di12 protein expression in breast tissues using Di12 antibody. Invasive ductal carcinoma, IDC (no special type, NST), grade IH, probed with Di12 antibody, immunoperoxidase staining, Fig. 4E (magnification 150x). Strands of infiltrating, pleomorphic cells (white →) and
35 areas of vascular space invasion (black →) stain strongly positive. Enlargement of Di12 positive cells from Fig. 4E shows diffused cytoplasmic staining with a slight increase of

stain in perinuclear regions (white →), Fig. 4F (1000x). IDC (NST), grade U, with retraction artifacts (space around islands of cells). Rounded cohesive islands of malignant cells show intensive cytoplasmic staining. Cells are only mildly pleomorphic with some tubular differentiation, Fig. 4G (150x). Normal breast tissue (from breast reduction) probed with Di12 antibody, showing normal appearance of a lobule with no specific peroxidase staining Fig. 4H (150x).

Fig. 5. Expression of Di12 in nominal and breast cancer tissue samples. RT-PCR of identical cDNA samples from various nominal and benign breast tissues were carried out with Di12 specific primers (top) and the housekeeping gene, porphobilinogen deaminase (bottom). PCR amplified products were analyzed on a 2% agarose gel. Lanes 1, 2, 3, and 9 contain IDC samples. Lane 6 contains intraductal papilloma sample, lane 4 contains benign tissue and samples in lanes 7, 8 and 10 are derived from fibroadenomas.

Fig. 6. Di12 gene product in breast cancer patient sera, data are representative samples of individuals graded and classified as indicated (n=3, +/- S.E). IDC accompanied by distant metastases, grade III, stage IV, IDCa. IDC with metastases, 3 of 16 axillary lymph nodes involved, grade III, stage III, IDCb. IDC no metastasis, grade I, stage I, IDCc. IDC with intraductal papilloma, no metastasis, IDC/IP. Ductal carcinoma in situ, DCIS. Line indicates cut-off levels for Di12 positive considered samples.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the discovery and characterization of a nucleic acid molecule encoding a Di12 protein whose expression is elevated in breast cancer tissue and cell lines.

In the development of breast neoplasia, there are a subset of genes that will be specifically expressed at various stages, and a certain number of these will be critical for the progression of malignancy, especially those associated with the metastatic spread of the disease. In

order to identify and isolate genes whose expression is associated with breast carcinomas in various stages of neoplastic development, subtractive-hybridization cloning and differential display-PCR (Schweinfest et al., 1990, *Gene Anal*
5 *Techn*, 7:64-70; Liang et al., 1992, *Science*, 257:967-971; Salesiotis et al., 1995, *Cancer Letters*, 91:47-54; Burger et al., 1996, *International Journal of Oncology*, 8:395-400) were employed. RNA was prepared from cell lines derived from a tumor and adjacent normal tissue of the same human patient.
10 cDNAs from the normal breast cell line was subtracted from cDNAs of the breast carcinoma cell line. Over 950 clones were obtained by subtractive cloning and twenty-four clones by differential display PCR. In all, 105 cDNAs were sequenced and analyzed by computer searching and 30 were
15 found to be unique. One of these novel cDNAs, designated herein as Di12, which may be associated with breast malignancy was selected for detailed characterization. A full length Di12 cDNA clone was isolated and antibodies were generated to study its distribution in breast cancer patient
20 sera and tumor samples. Once identified, these differentially expressed genes will be useful for diagnosis and for monitoring disease progression, as well as for facilitating the molecular definition of specific stages of tumor development. This information will also assist in
25 patient prognosis as well as in the selection of treatment modalities. In addition, molecular definition of new genes involved in breast tumors will yield novel targets for gene therapy and for therapeutic intervention.

The compositions of the invention described in the
30 following sections are recombinant mammalian Di12 DNA molecules, cloned genes, or degenerate variants thereof. Also described herein are nucleic acid probes useful for the identification of Di12 gene mutations and the use of such nucleic acid probes in diagnosing breast cancer. The
35 compositions of the present invention further include Di12 gene products (e.g., peptides, proteins) that are encoded by the Di12 gene. The present invention also provides

antibodies against Di12 gene products, or conserved variants or fragments thereof. Such antibodies can be used to measure the level of Di12 gene products in biological fluids and tissues of a patient. Thus, the present invention also
5 encompasses methods and kits for the diagnosis, prognosis and staging of breast cancer, and the monitoring of the effect of a therapeutic treatment.

Further provided are methods for the use of the Di12 gene and/or Di12 gene products in the identification of
10 compounds which modulate the expression of the Di12 gene. The Di12 gene is a novel gene of which the expression is upregulated in breast cancer cell lines and tissues. As such, the Di12 gene product can be involved in the mechanisms underlying the onset and development of breast cancer as well
15 as the regional infiltration and metastatic spread of breast cancer. Thus, the present invention also provides methods for the prevention and/or treatment of breast cancer, and for the control of metastatic spread of breast cancer that is based on modulation of the expression of Di12.

20

5.1 THE Di12 GENE

Nucleic acid sequences of the identified Di12 gene are described herein. The full-length Di12 cDNA (1363 bp) was cloned from a CEM cDNA library. The DNA sequence contains an
25 open reading frame of 339 amino acids. The gene sequence or amino acid sequence shows no homology to known genes or proteins. A deposit of the Di12 cDNA clone as a plasmid, pBS-Di12, in *E. coli* DH5 host was made at the American Type Culture Collection (ATCC), 12301 Parklawn Drive Rockville,
30 Maryland on March 20, 1998, under the Accession number _____.

As used herein, "Di12 gene" refers to (a) a gene containing the DNA sequence shown in Figure 1B; (b) any DNA sequence that hybridizes to the complement of the DNA sequences that encode the amino acid sequence shown in Figure
35 1A, under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at

68°C (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at page 2.10.3) or (c) any DNA sequence that hybridizes to the complement of the DNA
5 sequences that encode the amino acid sequence shown in Figure 1A, under moderately stringent conditions, e.g., washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, *supra*), and encodes a gene product functionally equivalent to an Di12 gene product encoded by sequences shown in Figure 1A yet
10 which still encodes a functionally equivalent Di12 gene product.

In one embodiment of the invention, Di12 gene may also encompass fragments and degenerate variants of DNA sequences (a) through (d), including naturally occurring variants
15 thereof. The Di12 gene fragment may be a complementary DNA (cDNA) molecule or a genomic DNA molecule that may comprise one or more intervening sequences or introns, as well as regulating regions located beyond the 5' and 3' ends of the coding region or within an intron.

20 A Di12 gene sequence preferably exhibits at least about 80% overall similarity at the nucleotide level to the nucleic acid sequence depicted in Figure 1B, more preferably exhibits at least about 85-90% overall similarity to the Figure 1B nucleic acid sequence and most preferably exhibits at least
25 about 95% overall similarity to the Figure 1B nucleic acid sequence.

The Di12 gene sequences of the invention are of mammalian origin, and most preferably human.

The Di12 gene sequences of the invention further include
30 isolated nucleic acid molecules which hybridize under highly stringent or moderate stringent conditions to at least about 6, preferably about 12, more preferably about 18, consecutive nucleotides of the Di12 gene sequences of (a)-(d).

The invention also includes nucleic acid molecules,
35 preferably DNA molecules, that hybridize to, and are therefore the complements of, the DNA sequences (a) through (d), in the preceding paragraph. Such hybridization

conditions may be highly stringent or moderately stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("oligos"), highly stringent conditions may refer, e.g., to washing in 5 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic acid molecules may encode or act as D112 gene antisense molecules useful, for example, in D112 gene regulation. With respect 10 to D112 gene regulation, such techniques can be used to modulate, for example, the phenotype and metastatic potential of breast cancer cells. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for D112 gene regulation.

15 Still further, such molecules may be used as components of diagnostic methods whereby, for example, the presence of a particular D112 allele or alternatively spliced D112 transcript responsible for causing or predisposing one to breast cancer or other cancers may be detected.

20 Still further, the invention encompassing D112 genes as a screen in an engineered yeast system, including, but not limited to, the yeast two hybrid system.

The invention also encompasses (a) DNA vectors that contain any of the foregoing D112 coding sequences and/or 25 their complements (e.g., antisense); (b) DNA expression vectors that contain any of the foregoing D112 coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences; and (c) genetically engineered host cells that contain any of the 30 foregoing D112 coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell. As used herein, regulatory elements include, but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements 35 known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the cytomegalovirus (hCMV) immediate early

promoter, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for
5 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

The invention includes fragments of any of the DNA sequences disclosed herein.

In addition to the Di12 gene sequences described above,
10 homologs of such sequences, exhibiting extensive homology to the Di12 gene product present in other species can be identified and readily isolated, without undue experimentation, by molecular biological techniques well known in the art. Further, there can exist homolog genes at
15 other genetic loci within the genome that encode proteins which have extensive homology to the Di12 gene product. These genes can also be identified via similar techniques. Still further, there can exist alternatively spliced variants of the Di12 gene.

20 As an example, in order to clone a mammalian Di12 gene homolog or variants using isolated human Di12 gene sequences as disclosed herein, such human Di12 gene sequences are labeled and used to screen a cDNA library constructed from mRNA obtained from appropriate cells or tissues (e.g., breast
25 epithelial cells) derived from the organism of interest.

With respect to the cloning of such a mammalian Di12 homolog, a mammalian breast cancer cell cDNA library may, for example, be used for screening.

The hybridization and wash conditions used should be of
30 a low stringency when the cDNA library is derived from a different type of organism than the one from which the labeled sequence was derived. Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which
35 the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold

Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

With respect to the cloning of a mammalian Dil2 homolog, 5 using human Dil2 sequences, for example, various stringency conditions which promote DNA hybridization can be used. For example, hybridization in 6x SSC at about 45°C, followed by washing in 2xSSC at 50°C may be used. Alternatively, the salt concentration in the wash step can range from low 10 stringency of about 5xSSC at 50°C, to moderate stringency of about 2xSSC at 50°C, to high stringency of about 0.2x SSC at 50°C. In addition, the temperature of the wash step can be increased from low stringency conditions at room temperature, to moderately stringent conditions at about 42°C, to high 15 stringency conditions at about 65°C. Other conditions include, but are not limited to, hybridizing at 68°C in 0.5M NaHPO₄ (pH7.2)/ 1 mM EDTA/ 7% SDS, or hybridization in 50% formamide/0.25M NaHPO₄ (pH 7.2)/.25 M NaCl/1 mM EDTA/7% SDS; followed by washing in 40 mM NaHPO₄ (pH 7.2)/1 mM EDTA/5% SDS 20 at 50°C or in 40 mM NaHPO₄ (pH7.2) 1 mM EDTA/1% SDS at 50°C. Both temperature and salt may be varied, or alternatively, one or the other variable may remain constant while the other is changed.

Alternatively, the labeled fragment may be used to 25 screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions well known to those of skill in the art.

Further, a Dil2 gene homolog may be isolated from nucleic acid of the organism of interest by performing PCR 30 using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the Dil2 gene product disclosed herein. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, mammalian cell lines or tissue known or 35 suspected to express a Dil2 gene homology or allele.

The PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a

Di12 gene nucleic acid sequence. The PCR fragment may then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment may be labeled and used to screen a cDNA library, such as a bacteriophage
5 cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

PCR technology may be utilized to isolate full length cDNA sequences. For example, RNA may be isolated, following
10 standard procedures, from an appropriate cellular or tissue source (e.g., one known, or suspected, to express the Di12 gene, such as, for example, breast cancer cell lines). A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end
15 of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" with guanines using a standard terminal transferase reaction, the hybrid may be digested with RNAase H, and second strand synthesis may then be primed with a poly-C primer. Thus,
20 cDNA sequences upstream of the amplified fragment may easily be isolated. For a review of PCR technology and cloning strategies which may be used, see e.g., PCR Primer, 1995, Dieffenbach et al., ed., Cold Spring Harbor Laboratory Press; Sambrook et al., 1989, *supra*.

25 Di12 gene sequences may additionally be used to isolate Di12 gene alleles and mutant Di12 gene alleles. Such mutant alleles may be isolated from individuals either known or susceptible to or predisposed to have a genotype which contributes to the development of breast cancer, including
30 metastasis. Mutant alleles and mutant allele products may then be utilized in the screening, therapeutic and diagnostic methods and systems described herein. Additionally, such Di12 gene sequences can be used to detect Di12 gene regulatory (e.g., promoter) defects which can affect the
35 development and outcome of breast cancer.

A cDNA of a mutant Di12 gene may be isolated, for example, by using PCR, a technique which is well known to

those of skill in the art. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively
5 carrying the mutant Di12 allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via
10 PCR, cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant Di12 allele to that of the normal Di12 allele, the mutation(s) responsible for the loss or alteration of
15 function of the mutant Di12 gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry the mutant Di12 allele, or a cDNA library can be constructed using RNA from a tissue known, or suspected, to
20 express the mutant Di12 allele. The normal Di12 gene or any suitable fragment thereof may then be labeled and used as a probe to identify the corresponding mutant Di12 allele in such libraries. Clones containing the mutant Di12 gene sequences may then be purified and subjected to sequence
25 analysis according to methods well known to those of skill in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant Di12
30 allele. In this manner, gene products made from the mutant allele may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal Di12 gene product, as described, below, in Section 5.3. (For screening techniques, see, for example,
35 Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.) In cases where a Di12 mutation results in an expressed gene

product with altered function (e.g., as a result of a missense or a frameshift mutation), a set of polyclonal antibodies to Di12 gene product are likely to cross-react with the mutant Di12 gene product. Library clones detected
5 via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

5.2 PROTEIN PRODUCTS OF THE Di12 GENE

10 In another embodiment, the present invention provides Di12 gene products, or peptide fragments thereof which can be used for the generation of antibodies, in diagnostic assays, or for the identification of other cellular gene products involved in the development of cancer, such as, for example,
15 breast cancer.

The amino acid sequence depicted in Figure 1A represents a Di12 gene product. The Di12 gene product, sometimes referred to herein as a "Di12 protein", may additionally include those gene products encoded by the Di12 gene
20 sequences described in Section 5.1, above.

The Di12 gene product comprises 339 amino acids. Using the Genetics Computing Group UW MOTIFS program we found: four consensus (N-X-S/T) N-glycosylation sites at positions 62, 65, 196, 277; six Ck-2 sites (consensus S/T-X-X-D/E) at
25 positions 67, 137, 163, 189, 199, and 235; seven protein kinase C (PKC) sites (consensus S-X-K) at positions 7, 10, 100, 124, 165, 189, and 248; and various myristoylation sites. The PEPLOT program predicts several hydrophobic regions in the Di12 protein, including a hydrophobic tail at
30 the C-terminus. To confirm the open reading frame, the Di12 cDNA was used in an *in vitro* coupled transcription-translation system. As expected, a 35 kD protein was produced which is recognized by anti-Di12 antibodies in immunoprecipitation assays.

35 In addition, Di12 gene products may include proteins that represent functionally equivalent gene products. Such an equivalent Di12 gene product may contain deletions, additions

or substitutions of amino acid residues within the amino acid sequence encoded by the D112 gene sequences described, above, in Section 5.1, but which result in a silent change, thus producing a functionally equivalent D112 gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

"Functionally equivalent", as utilized herein, refers to a protein capable of exhibiting a substantially similar in vivo activity as the endogenous D112 gene products encoded by the D112 gene sequences described in Section 5.1, above. The in vivo activity of the D112 gene product, as used herein, refers to its association of preneoplastic and neoplastic transformation of a cell when present in an appropriate cell type, such as may, for example, occur in the onset and progression and metastasis of breast cancer.

A D112 gene product sequence preferably exhibits at least about 80% overall similarity at the amino acid level to the amino acid sequence depicted in Figure 1A, more preferably exhibits at least about 90% overall similarity to the Figure 1A amino acid sequence and most preferably exhibits at least about 95% overall similarity to the Figure 1A amino acid sequence.

D112 gene products can also include fusion proteins comprising a D112 gene product sequence as described in this section operatively associated to a heterologous, e.g., peptide, component. Heterologous components can include, but are not limited to sequences which facilitate isolation and purification of fusion protein, such as a matrix binding

domain, or label components. Such isolation and label components are well known to those of skill in the art.

The D112 gene products or peptide fragments thereof, or fusion proteins can be used in any assay that detects or
5 measures D112 gene products or in the calibration and standardization of such assay.

The D112 gene products or peptide fragments thereof, may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing the D112
10 gene polypeptides and peptides of the invention by expressing nucleic acid containing D112 gene sequences are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing D112 gene product coding sequences and appropriate
15 transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook et al., 1989, *supra*, and Ausubel et al., 1989,
20 *supra*. Alternatively, RNA capable of encoding D112 gene product sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference
25 herein in its entirety.

A variety of host-expression vector systems may be utilized to express the D112 gene coding sequences of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and
30 subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the D112 gene product of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*)
35 transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing D112 gene product coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*)

transformed with recombinant yeast expression vectors containing the Di12 gene product coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the Di12 gene product coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing Di12 gene product coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the Di12 gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of Di12 protein or for raising antibodies to Di12 protein, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the Di12 gene product coding sequence may be ligated individually into the vector in frame with the *lac Z* coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that

the cloned target gene product can be released from the GST moiety.

In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express 5 foreign genes. The virus grows in Spodoptera frugiperda cells. The D112 gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). 10 Successful insertion of D112 gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera 15 frugiperda cells in which the inserted gene is expressed. (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an 20 adenovirus is used as an expression vector, the D112 gene coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or 25 in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing D112 gene product in infected hosts. (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). 30 Specific initiation signals may also be required for efficient translation of inserted D112 gene product coding sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire D112 gene, including its own initiation codon and adjacent sequences, is 35 inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the D112 gene

coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence
5 to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription
10 terminators, etc. (see Bittner et al., 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific
15 fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins
20 and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript,
25 glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB26, BT20 and T47D, and normal mammary gland
30 cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the Di12 gene product may be engineered. Rather than using expression vectors which
35 contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences,

transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a
5 selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to
10 engineer cell lines which express the Di12 gene product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the Di12 gene product.

A number of selection systems may be used, including but
15 not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine
phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817)
20 genes can be employed in tk⁻, hgp^rt⁻ or ap^rt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc.
25 Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hyg^r, which confers resistance to
30 hygromycin (Santerre, et al., 1984, Gene 30:147).

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-
35 denatured fusion proteins expressed in human cell lines (Janknecht, et al.; 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976). In this system, the gene of interest is

subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein.

5 Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni^{2+} -nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

The D112 gene products can also be expressed in
10 transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, sheep, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate D112 transgenic animals.

15 Any technique known in the art may be used to introduce the D112 gene transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus
20 mediated gene transfer into germ lines (Van der Putten et al., 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson et al., 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814); and sperm-mediated gene transfer
25 (Lavitrano et al., 1989, Cell 57:717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals
30 that carry the D112 transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals. The transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be
35 selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, M. et al., 1992, Proc. Natl. Acad. Sci. USA 89:

6232-6236). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the D112 gene transgene
5 be integrated into the chromosomal site of the endogenous D112 gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous D112 gene are designed for the purpose of integrating, via homologous
10 recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous D112 gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous D112 gene in only that cell type, by following, for example,
15 the teaching of Gu et al. (Gu, et al., 1994, Science 265: 103-106). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest; and will be apparent to those of skill in the art.

20 Methods for the production of single-copy transgenic animals with chosen sites of integration are also well known to those of skill in the art. See, for example, Bronson et al. (Bronson, S.K. et al., 1996, Proc. Natl. Acad. Sci. USA 93:9067-9072), which is incorporated herein by reference in
25 its entirety.

Once transgenic animals have been generated, the expression of the recombinant D112 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to
30 analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include but are not limited to Northern blot analysis of tissue samples obtained
35 from the animal, in situ hybridization analysis, and RT-PCR. Samples of D112 gene-expressing tissue, may also be evaluated

immunocytochemically using antibodies specific for the Di12 transgene product.

5.3 ANTIBODIES TO Di12 GENE PRODUCTS

5 In another embodiment, the present invention encompasses antibodies or fragments thereof capable of specifically recognizing one or more Di12 gene product epitopes or epitopes of conserved variants or peptide fragments of the Di12 gene products. Such antibodies may include, but are not
10 limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, Fv fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments
15 of any of the above.

Such antibodies may be used, for example, in the detection of a Di12 gene product in an biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for
20 abnormal levels of Di12 gene products, and/or for the presence of abnormal forms of the such gene products. Such antibodies may also be included as a reagent in a kit for use in a diagnostic or prognostic technique. Such antibodies may also be utilized in conjunction with, for example, compound
25 screening schemes, as described, below, in Section 5.4.2, for the evaluation of the effect of test compounds on Di12 gene product levels and/or activity. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described, below, in Section 5.4.3, to, for
30 example, evaluate the normal and/or engineered Di12-expressing cells prior to their introduction into the patient.

Antibodies to anti-Di12 gene product may additionally be used in a method for the inhibition of abnormal Di12 gene
35 product activity. Thus, such antibodies may, therefore, be utilized as part of cancer treatment methods.

Described herein are methods for the production of antibodies of such antibodies or fragments thereof. Any of such antibodies or fragments thereof may be produced standard immunological methods or by recombinant expression of nucleic acid molecules encoding the antibody or fragments thereof in an appropriate host organism.

For the production of antibodies against a Di12 gene product, various host animals may be immunized by injection with a Di12 gene product, or a portion thereof. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as a Di12 gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with Di12 gene product supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such

antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo
5 makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by
10 splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species,
15 such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird,
20 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against D112 gene products. Single chain antibodies are formed by linking the heavy and light chain
25 fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., 1988, Science 242:1038-1041).

Antibody fragments which recognize specific epitopes may
30 be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂
35 fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to

allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

5.4 USES OF THE D112 GENE, GENE PRODUCTS, AND ANTIBODIES

5 In various embodiments, the present invention provides various uses of the D112 gene, the D112 gene product including peptide fragments thereof, and of antibodies directed against the D112 gene product and peptide fragments thereof. Such uses include, for example, prognostic and
10 diagnostic evaluation of cancer, and the identification of subjects with a predisposition to a cancer, as described, below.

In one embodiment, the present invention provides a variety of methods for the diagnostic and prognostic
15 evaluation of breast cancer. Such methods may, for example, utilize reagents such as the D112 gene nucleotide sequences described in Sections 5.1, and antibodies directed against D112 gene products, including peptide fragments thereof, as described, above, in Section 5.2. Specifically, such
20 reagents may be used, for example, for: (1) the detection of the presence of D112 gene mutations, or the detection of either over- or under-expression of D112 gene mRNA preneoplastic or neoplastic relative to normal cells or the qualitative or quantitative detection of other allelic forms
25 of D112 transcripts which may correlate with breast cancer or susceptibility toward neoplastic changes, and (2) the detection of an over-abundance of D112 gene product relative to the non-disease state or the presence of a modified (e.g., less than full length) D112 gene product which correlates
30 with a neoplastic state or a progression toward neoplasia or metastasis.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic test kits comprising at least one specific D112 gene nucleic acid or
35 anti-D112 gene antibody reagent described herein, which may be conveniently used, e.g., in clinical settings or in home settings, to diagnose patients exhibiting preneoplastic or

neoplastic abnormalities, and to screen and identify those individuals exhibiting a predisposition to such neoplastic changes.

Nucleic acid-based detection techniques are described, below, in Section 5.4.1. Peptide detection techniques are described, below, in Section 5.4.2.

5.4.1 DETECTION OF D112 GENE NUCLEIC ACID MOLECULES

Mutations or polymorphisms within the D112 gene can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard nucleic acid preparation procedures which are well known to those of skill in the art. For the detection of D112 mutations, any nucleated cell can be used as a starting source for genomic nucleic acid. For the detection of D112 transcripts or D112 gene products, any cell type or tissue in which the D112 gene is expressed, such as, for example, breast cancer cells, including metastases, may be utilized.

Genomic DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving D112 gene structure, including point mutations, insertions, deletions and chromosomal rearrangements. Such assays may include, but are not limited to, direct sequencing (Wong, C. et al., 1987, Nature 330:384-386), single stranded conformational polymorphism analyses (SSCP; Orita, M. et al., 1989, Proc. Natl. Acad. Sci. USA 86:2766-2770), heteroduplex analysis (Keen, T.J. et al., 1991, Genomics 11:199-205; Perry, D.J. & Carrell, R.W., 1992), denaturing gradient gel electrophoresis (DGGE; Myers, R.M. et al., 1985, Nucl. Acids Res. 13:3131-3145), chemical mismatch cleavage (Cotton, R.G. et al., 1988, Proc. Natl. Acad. Sci. USA 85:4397-4401) and oligonucleotide hybridization (Wallace, R.B. et al., 1981, Nucl. Acids Res. 9:879-894; Lipshutz, R.J. et al., 1995, Biotechniques 19:442-447).

Diagnostic methods for the detection of Di12 gene specific nucleic acid molecules, in patient samples or other appropriate cell sources, may involve the amplification of specific gene sequences, e.g., by the polymerase chain reaction (PCR; see Mullis, K.B., 1987, U.S. Patent No. 4,683,202), followed by the analysis of the amplified molecules using techniques well known to those of skill in the art, such as, for example, those listed above. Utilizing analysis techniques such as these, the amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of the Di12 gene in order to determine whether a Di12 gene mutation exists.

Further, well-known genotyping techniques can be performed to type polymorphisms that are in close proximity to mutations in the Di12 gene itself. These polymorphisms can be used to identify individuals in families likely to carry mutations. If a polymorphism exhibits linkage disequilibrium with mutations in the Di12 gene, it can also be used to identify individuals in the general population likely to carry mutations. Polymorphisms that can be used in this way include restriction fragment length polymorphisms (RFLPs), which involve sequence variations in restriction enzyme target sequences, single-base polymorphisms and simple sequence repeat polymorphisms (SSLPs).

For example, Weber (U.S. Pat. No. 5,075,217, which is incorporated herein by reference in its entirety) describes a DNA marker based on length polymorphisms in blocks of (dC-dA)_n-(dG-dT)_n short tandem repeats. The average separation of (dC-dA)_n-(dG-dT)_n blocks is estimated to be 30,000-60,000 bp. Markers which are so closely spaced exhibit a high frequency co-inheritance, and are extremely useful in the identification of genetic mutations, such as, for example, mutations within the Di12 gene, and the diagnosis of diseases and disorders related to Di12 mutations.

Also, Caskey et al. (U.S. Pat.No. 5,364,759, which is incorporated herein by reference in its entirety) describe a

DNA profiling assay for detecting short tri and tetra nucleotide repeat sequences. The process includes extracting the DNA of interest, such as the Di12 gene, amplifying the extracted DNA, and labelling the repeat sequences to form a
5 genotypic map of the individual's DNA.

A Di12 probe could additionally be used to directly identify RFLPs. Additionally, a Di12 probe or primers derived from the Di12 sequence could be used to isolate genomic clones such as YACs, BACs, PACs, cosmids, phage or
10 plasmids. The DNA contained in these clones can be screened for single-base polymorphisms or simple sequence length polymorphisms (SSLPs) using standard hybridization or sequencing procedures.

Alternative diagnostic methods for the detection of Di12
15 gene-specific mutations or polymorphisms can include hybridization techniques which involve for example, contacting and incubating nucleic acids including recombinant DNA molecules, cloned genes or degenerate variants thereof, obtained from a sample, e.g., derived from a patient sample
20 or other appropriate cellular source, with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate variants thereof, as described in Section 5.1, under conditions favorable for the specific annealing of these reagents to their complementary
25 sequences within the Di12 gene. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:Di12 molecule hybrid. The presence of nucleic acids which have hybridized, if any
30 such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the cell type or tissue of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this
35 case, after incubation, non-annealed, labeled nucleic acid reagents of the type described in Section 5.1 are easily removed. Detection of the remaining, annealed, labeled Di12

nucleic acid reagents is accomplished using standard techniques well-known to those in the art. The D112 gene sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal D112 gene sequence in order to determine whether a D112 gene mutation is present.

Quantitative and qualitative aspects of D112 gene expression can also be assayed. For example, RNA from a cell type or tissue known, or suspected, to express the D112 gene, such as breast cancer cells, including metastases, may be isolated and tested utilizing hybridization or PCR techniques as described, above. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the D112 gene. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the D112 gene, including activation or inactivation of D112 gene expression and presence of alternatively spliced D112 transcripts.

In one embodiment of such a detection scheme, a cDNA molecule is synthesized from an RNA molecule of interest by reverse transcription. All or part of the resulting cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method are chosen from among the D112 gene nucleic acid reagents described in Section 5.1. The preferred lengths of such nucleic acid reagents are at least 9-30 nucleotides.

For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be

visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.

Such RT-PCR techniques can be utilized to detect differences in D112 transcript size which may be due to normal or abnormal alternative splicing. Additionally, such techniques can be performed using standard techniques to detect quantitative differences between levels of full length and/or alternatively spliced D112 transcripts detected in normal individuals relative to those individuals having cancer or exhibiting a predisposition toward neoplastic changes.

In the case where detection of specific alternatively spliced species is desired, appropriate primers and/or hybridization probes can be used, such that, in the absence of such sequence, no amplification would occur.

Alternatively, primer pairs may be chosen utilizing the sequence data depicted in Figure 1B to choose primers which will yield fragments of differing size depending on whether a particular exon is present or absent from the transcript D112 transcript being utilized.

As an alternative to amplification techniques, standard Northern analyses can be performed if a sufficient quantity of the appropriate cells can be obtained. Utilizing such techniques, quantitative as well as size related differences between D112 transcripts can also be detected.

Additionally, it is possible to perform such D112 gene expression assays "in situ", *i.e.*, directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents such as those described in Section 5.1 may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G.J., 1992, "PCR In Situ Hybridization: Protocols And Applications", Raven Press, NY).

5.4.2 DETECTION OF D112 GENE PRODUCTS

Antibodies directed against wild type or mutant D112 gene products or conserved variants or peptide fragments thereof, which are discussed, above, in Section 5.2, may also
5 be used as diagnostics and prognostics, as described herein. Such diagnostic methods, may be used to detect abnormalities in the level of D112 gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of D112 gene product. Antibodies, or fragments of
10 antibodies, such as those described below, may be used to screen potentially therapeutic compounds in vitro to determine their effects on D112 gene expression and D112 peptide production. The compounds which have beneficial effects on breast cancer can be identified and a
15 therapeutically effective dose determined.

The tissue or cell type to be analyzed will generally include those which are known, or suspected, to express the D112 gene, such as, for example, breast cancer cells or metastatic cells. The protein isolation methods employed
20 herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety. The isolated cells can be derived
25 from cell culture or from a patient. The analysis of cell taken from culture may be a necessary step to test the effect of compounds on the expression of the D112 gene.

Preferred diagnostic methods for the detection of D112 gene products or conserved variants or peptide fragments
30 thereof, may involve, for example, immunoassays wherein the D112 gene products or conserved variants, including gene products which are the result of alternatively spliced transcripts, or peptide fragments are detected by their interaction with an anti-D112 gene product-specific antibody.

35 For example, antibodies, or fragments of antibodies, such as those described, above, in Section 5.3, useful in the present invention may be used to quantitatively or

qualitatively detect the presence of Di12 gene products or conserved variants or peptide fragments thereof. The antibodies (or fragments thereof) useful in the present invention may, additionally, be employed histologically, as
5 in immunofluorescence or immunoelectron microscopy, for in situ detection of Di12 gene products or conserved variants or peptide fragments thereof. In situ detection may be accomplished by removing a histological specimen from a patient, such as paraffin embedded sections of breast tissues
10 and applying thereto a labeled antibody of the present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Since the Di12 gene product is present in the cytoplasm, it may be desirable to introduce the antibody
15 inside the cell, for example, by making the cell membrane permeable. Through the use of such a procedure, it is possible to determine not only the presence of the Di12 gene product, or conserved variants or peptide fragments, but also its distribution in the examined tissue. Using the present
20 invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

Immunoassays for Di12 gene products or conserved
25 variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of identifying Di12 gene
30 products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample may be brought in contact with and
35 immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by

treatment with the detectably labeled D112 gene specific antibody. The solid phase support may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on solid support may then be detected
5 by conventional means.

By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases,
10 natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled
15 molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.
20 Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of anti-D112 gene
25 product antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

One of the ways in which the D112 gene peptide-specific
30 antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller, A. et al.,
35 1978, J. Clin. Pathol. 31:507-520; Butler, J.E., 1981, Meth. Enzymol. 73:482-523; Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL; Ishikawa, E. et al.,

(eds.), 1981, Enzyme Immunoassay, Kigaku Shoin, Tokyo). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be
5 detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-
10 glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by
15 colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection may also be accomplished using any of a
20 variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect Dil2 gene peptides through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on
25 Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

30 It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are
35 fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

The antibody can also be detectably labeled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as

5 diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by

10 detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

15 Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent

20 protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

In various embodiments, the present invention provides the measurement of D112 gene products, and the uses of such

25 measurements in clinical applications.

As used herein, the term "soluble" shall mean those molecules that are "spontaneously released"; i.e., released by normal or pathologic physiological processes of a cell.

The measurement of D112 gene product of the invention

30 can be valuable in detecting and/or staging breast cancer in a subject, in screening of breast cancer in a population, in differential diagnosis of the physiological condition of a subject, and in monitoring the effect of a therapeutic treatment on a subject.

35 The present invention also provides for the detecting, diagnosing, or staging of breast cancer, or the monitoring of treatment of breast cancer by measuring in addition to D112

gene product at least one other marker, such as receptors or differentiation antigens. For example, serum markers selected from, for example but not limited to, carcinoembryonic antigen (CEA), CA15-3, CA549, CAM26, M29, 5 CA27.29 and MCA can be measured in combination with D112 gene product to detect, diagnose, stage, or monitor treatment of breast cancer. In another embodiment, the prognostic indicator is the observed change in different marker levels relative to one another, rather than the absolute levels of 10 the markers present at any one time. These measurements can also aid in predicting therapeutic outcome and in evaluating and monitoring the overall disease status of a subject.

In a specific embodiment of the invention, soluble D112 gene product alone or in combination with other markers can 15 be measured in any body fluid of the subject including but not limited to blood, serum, plasma, milk, urine, saliva, pleural effusions, synovial fluid, spinal fluid, tissue infiltrations and tumor infiltrates. The measurement of soluble D112 gene products in blood or serum is preferred 20 with respect to the development of a test kit which is to be used in clinics and homes.

Any of numerous immunoassays can be used in the practice of the instant invention, such as those described in Section 5.4.2. Antibodies, or antibody fragments containing the 25 binding domain, which can be employed include but are not limited to suitable antibodies among those in Section 5.3 and other antibodies known in the art or which can be obtained by procedures standard in the art such as those described in Section 5.3.

30

5.4.3 DETECTING AND STAGING A BREAST CANCER IN A SUBJECT

In one embodiment of the present invention, measurement of D112 gene product or fragment thereof, or soluble D112 35 gene product can be used to detect breast cancer in a subject or to stage the breast cancer in a subject.

Staging refers to the grouping of patients according to the extent of their disease. Staging is useful in choosing treatment for individual patients, estimating prognosis, and comparing the results of different treatment programs.

- 5 Staging of breast cancer is performed initially on a clinical basis, according to the physical examination and laboratory radiologic evaluation. The most widely used clinical staging system is the one adopted by the International Union against Cancer (UICC) and the American Joint Committee on Cancer
- 10 (AJCC) Staging and End Results Reporting. It is based on the tumor-nodes-metastases (TNM) system as detailed in the 1988 Manual for *Staging of Cancer*. Breast cancer diseases or conditions which may be detected and/or staged in a subject according to the present invention include but are not
- 15 limited to those listed in Table I.

20

25

30

35

TABLE I

STAGING OF BREAST CANCER

		PRIMARY TUMORS
5	T	
	TX	Primary tumor cannot be assessed
	T0	No evidence of primary tumor
	Tis	Carcinoma in situ: intraductal carcinoma, lobular carcinoma, or Paget's disease with no tumor
10	T1	Tumor 2 cm or less in its greatest dimension
		a. 0.5 cm or less in greatest dimension
		b. Larger than 0.5 cm, but not larger than 1 cm in greatest dimension
		c. Larger than 1 cm, but not larger than 2 cm in greatest dimension
	T2	Tumor more than 2 cm but not more than 5 cm in greatest dimension
15	T3	Tumor more than 5cm in its greatest dimension
	T4	Tumor of any size with direct extension to chest wall or to skin. Chest wall includes ribs, intercostal muscles, and serratus anterior muscle, but not pectoral muscle.
		a. Extension to chest wall
20		b. Edema (including peau d'orange), ulceration of the skin of the breast, or satellite skin nodules confined to the same breast
		c. Both of the above
		d. Inflammatory carcinoma
25	Dimpling of the skin, nipple retraction, or any other skin changes except those in T4b may occur in T1, T2 or T3 without affecting the classification.	
		REGIONAL LYMPH NODES
30	N	
	NX	Regional lymph nodes cannot be assessed (e.g., previously removed)
	N0	No regional lymph node metastases
	N1	Metastasis to movable ipsilateral axillary node(s)
	N2	Metastases to ipsilateral axillary nodes fixed to one another or to other structures
35	N3	Metastases to ipsilateral internal mammary lymph node(s)

M	DISTANT METASTASIS
M0	No evidence of distant metastasis
M1	Distant metastases (including metastases to ipsilateral supraclavicular lymph nodes)

5

Any immunoassay, such as those described in Section 5.4.2 can be used to measure the amount of D112 gene product or soluble D112 gene product which is compared to a baseline level. This baseline level can be the amount which is
10 established to be normally present in the tissue or body fluid of subjects with various degrees of the disease or disorder. An amount present in the tissue or body fluid of the subject which is similar to a standard amount,
15 established to be normally present in the tissue or body fluid of the subject during a specific stage of breast cancer, is indicative of the stage of the disease in the subject. The baseline level could also be the level present in the subject prior to the onset of disease or the amount present during remission of the disease.

20 In specific embodiments of this aspect of the invention, measurements of levels of the D112 gene product or soluble D112 gene product can be used in the detection of infiltrative ductal carcinoma (IDC) or the presence of metastases or both. Progressively higher levels of D112 gene
25 products or soluble D112 gene product are associated with IDC, and more aggressive forms of the disease, such as IDC with regional lymph node involvement, and IDC with distant metastases.

30 In another embodiment of the invention, the measurement of soluble D112 gene product, fragments thereof or immunologically related molecules can be used to differentially diagnose in a subject a particular disease phenotype or physiological condition as distinct as from
35 among two or more phenotypes or physiological conditions. For example, measurements of D112 gene product or soluble D112 gene product levels may be used in the differential

diagnosis of infiltrative ductal carcinoma, as distinguished from ductal carcinoma in situ or benign fibroadenomas. To this end, for example, the measured amount of the soluble Di12 gene product is compared with the amount of the soluble molecule normally present in body fluid of a subject with one of the suspected physiological conditions. A measured amount of the soluble molecule similar to the amount normally present in a subject with one of the physiological conditions, and not normally present in a subject with one or more of the other physiological conditions, is indicative of the physiological condition of the subject.

5.4.4 MONITORING THE EFFECT OF A THERAPEUTIC TREATMENT

The present invention provides a method for monitoring the effect of a therapeutic treatment on a subject who has undergone the therapeutic treatment.

Clinicians very much need a procedure that can be used to monitor the efficacy of these treatments. Soluble Di12 gene product can be identified and detected in breast cancer patients with different manifestations of disease, providing a sensitive assay to monitor therapy. The therapeutic treatments which may be evaluated according to the present invention include but are not limited to radiotherapy, surgery, chemotherapy, vaccine administration, endocrine therapy, immunotherapy, and gene therapy, etc. The chemotherapeutic regimens include, but are not limited to administration of drugs such as, for example, methotrexate, fluorouracil, cyclophosphamide, doxorubicin, and taxol. The endocrine therapeutic regimens include, but are not limited to administration of tamoxifen, progestins, etc.

The method of the invention comprises measuring at suitable time intervals before, during, or after therapy, the amount of a Di12 gene product or soluble Di12 gene product, or both. Any change or absence of change in the amount of the Di12 gene product or soluble Di12 gene product or in the

amount of the total Di12 gene product can be identified and correlated with the effect of the treatment on the subject.

In particular, the serum levels of soluble Di12 gene product bears a direct relationship with severity of breast cancer and poor prognosis. Since serum soluble Di12 gene product levels are generally undetectable or negligible in normal individuals, generally, a decrease in the level of detectable soluble Di12 gene product after a therapeutic treatment is associated with efficacious treatment.

10 In a preferred aspect, the approach that can be taken is to determine the levels of soluble Di12 gene product levels at different time points and to compare these values with a baseline level. The baseline level can be either the level of the marker present in normal, disease free individuals;
15 and/or the levels present prior to treatment, or during remission of disease, or during periods of stability. These levels can then be correlated with the disease course or treatment outcome.

20 5.5 SCREENING ASSAYS FOR COMPOUNDS
THAT MODULATE Di12 ACTIVITY

The present invention further provides methods for the identification of compounds that may, through its interaction with the Di12 gene or Di12 gene product, affect the onset,
25 progression and metastatic spread of breast cancer.

The following assays are designed to identify: (i) compounds that bind to Di12 gene products; (ii) compounds that bind to other intracellular proteins that interact with a Di12 gene product; (iii) compounds that interfere with the
30 interaction of the Di12 gene product with other intracellular proteins; and (iv) compounds that modulate the activity of Di12 gene (i.e., modulate the level of Di12 gene expression and/or modulate the level of Di12 gene product activity).

Assays may additionally be utilized which identify
35 compounds which bind to Di12 gene regulatory sequences (e.g., promoter sequences). See e.g., Platt, K.A., 1994, J. Biol. Chem. 269:28558-28562, which is incorporated herein by

reference in its entirety, which may modulate the level of Di12 gene expression.

Such intracellular proteins may be involved in the onset, development and metastatic spread of breast cancer.

5 Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the Di12 gene product, and for ameliorating symptoms of breast cancer. Assays for testing the effectiveness of compounds, identified by, for example, 10 techniques such as those described in Section 5.5.1, are discussed, below, in Section 5.5.3. It is to be noted that the compositions of the invention include pharmaceutical compositions comprising one or more of the compounds identified via such methods. Such pharmaceutical 15 compositions can be formulated, for example, as discussed, below, in Section 5.7.

5.5.1 **IN VITRO SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO THE Di12 GENE PRODUCT**

20 In vitro systems may be designed to identify compounds capable of interacting with, e.g., binding to, the Di12 gene products of the invention. Compounds identified may be useful, for example, in modulating the activity of wild type and/or mutant Di12 gene products, may be useful in 25 elaborating the biological function of the Di12 gene product, may be utilized in screens for identifying compounds that disrupt normal Di12 gene product interactions, or may in themselves disrupt such interactions.

30 The principle of the assays used to identify compounds that interact with the Di12 gene product involves preparing a reaction mixture of the Di12 gene product and the test compound under conditions and for a time sufficient to allow the two components to interact with, e.g., bind to, thus forming a complex, which can represent a transient complex, 35 which can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve

anchoring Di12 gene product or the test substance onto a solid phase and detecting Di12 gene product/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the Di12 gene
5 product may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be
10 immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein to be
15 immobilized may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete,
20 unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized component is
25 pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the
30 previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid
3 phase, the reaction products separated from unreacted
35 components, and complexes detected; e.g., using an immobilized antibody specific for Di12 gene product or the test compound to anchor any complexes formed in solution, and

a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

**5.5.2 ASSAYS FOR INTRACELLULAR PROTEINS
THAT INTERACT WITH THE Di12 GENE PRODUCT**

5

Any method suitable for detecting protein-protein interactions may be employed for identifying Di12 protein-intracellular protein interactions.

Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns. Utilizing procedures such as these allows for the isolation of intracellular proteins which interact with Di12 gene products. Once isolated, such an intracellular protein can be identified and can, in turn, be used, in conjunction with standard techniques, to identify additional proteins with which it interacts. For example, at least a portion of the amino acid sequence of the intracellular protein which interacts with the Di12 gene product can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique (see, e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles", W.H. Freeman & Co., N.Y., pp.34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such intracellular proteins. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, e.g., Ausubel, supra., and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds. Academic Press, Inc., New York).

Additionally, methods may be employed which result in the simultaneous identification of genes which encode the intracellular protein interacting with the Di12 protein. These methods include, for example, probing expression libraries with labeled Di12 protein, using Di12 protein in a

manner similar to the well known technique of antibody probing of λ gt11 libraries.

One method which detects protein interactions in vivo, the two-hybrid system, can be used. One version of this system has been described (Chien et al., 1991, Proc. Natl. Acad. Sci. USA, 88:9578-9582) and is commercially available from Clontech (Palo Alto, CA).

10 5.5.3 **ASSAYS FOR COMPOUNDS THAT INTERFERE
WITH D112 GENE PRODUCT/INTRACELLULAR
MACROMOLECULAR INTERACTION**

15 The D112 gene products of the invention may, in vivo, interact with one or more intracellular macromolecules, such as proteins. Such macromolecules may include, but are not limited to, nucleic acid molecules and those proteins identified via methods such as those described, above, in Section 5.5.2. For purposes of this discussion, such intracellular macromolecules are referred to herein as "interacting partners". Compounds that disrupt D112 interactions in this way may be useful in regulating the activity of the D112 gene product, including mutant D112 gene products. Such compounds may include, but are not limited to molecules such as peptides, and the like, as described, for example, in Section 5.5.1. above, which would be capable of gaining access to the intracellular D112 gene product.

25 The basic principle of the assay systems used to identify compounds that interfere with the interaction between the D112 gene product and its intracellular interacting partner or partners involves preparing a reaction mixture containing the D112 gene product, and the interacting partner under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of D112 gene product and its

intracellular interacting partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the Dil2 gene protein and the intracellular interacting partner is then detected.

5 The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the Dil2 gene protein and the interacting partner. Additionally, complex formation within reaction mixtures

10 containing the test compound and normal Dil2 gene protein may also be compared to complex formation within reaction mixtures containing the test compound and a mutant Dil2 gene protein. This comparison may be important in those cases wherein it is desirable to identify compounds that disrupt

15 interactions of mutant but not normal Dil2 gene proteins.

The assay for compounds that interfere with the interaction of the Dil2 gene products and interacting partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the

20 Dil2 gene product or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to

25 obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the Dil2 gene products and the interacting partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test

30 substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the Dil2 gene protein and intracellular interacting partner. Alternatively, test compounds that disrupt preformed complexes, e.g. compounds

35 with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

In a heterogeneous assay system, either the D112 gene product or the interacting partner, is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly. In practice, microtiter plates are
5 conveniently utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the D112 gene product or interacting partner and drying. Alternatively, an
10 immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or
15 without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the
20 non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody
25 specific for the initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed
30 complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and
35 complexes detected; e.g., using an immobilized antibody specific for one of the interacting components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again,

depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a
5 homogeneous assay can be used. In this approach, a preformed complex of the Di12 gene protein and the interacting partner is prepared in which either the Di12 gene product or its interacting partners is labeled, but the signal generated by the label is quenched due to complex formation (see, e.g.,
10 U.S. Patent No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays).. The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances which disrupt
15 Di12 gene protein/intracellular interacting partner interaction can be identified.

In a particular embodiment, the Di12 gene product can be prepared for immobilization using recombinant DNA techniques described in Section 5.1, above. For example, the Di12
20 coding region can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its interacting activity is maintained in the resulting fusion protein. The intracellular interacting partner can be purified and used to raise a monoclonal
25 antibody, using methods routinely practiced in the art and described above, in Section 5.2. This antibody can be labeled with the radioactive isotope ¹²⁵I, for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., the GST-Di12 fusion protein can be anchored to
30 glutathione-agarose beads. The intracellular interacting partner can then be added in the presence or absence of the test compound in a manner that allows interaction, e.g., binding, to occur. At the end of the reaction period, unbound material can be washed away, and the labeled
35 monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between the Di12 gene protein and the intracellular interacting

partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured
5 radioactivity.

Alternatively, the GST-Di12 gene fusion protein and the intracellular interacting partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the
10 species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the Di12 gene product/interacting partner interaction can be detected by adding the labeled antibody and measuring the
15 radioactivity associated with the beads.

5.5.4 CELL-BASED ASSAYS FOR IDENTIFICATION OF COMPOUNDS WHICH MODULATE Di12 ACTIVITY

Cell-based methods are presented herein which identify
20 compounds capable of treating breast cancer by modulating Di12 activity. Specifically, such assays identify compounds which affect Di12-dependent processes, such as but not limited to changes in cell morphology, cell division, differentiation, adhesion, motility, or phosphorylation,
25 dephosphorylation of cellular proteins. Compounds identified via such methods can, for example, be utilized in methods for treating breast cancer and metastasis.

In one embodiment, the cell-based assays are based on expression of the Di12 gene product in a mammalian cell and
30 measuring the Di12-dependent process. Any mammalian cells that can express the Di12 gene and allow the functioning of the Di12 gene product can be used, in particular, cancer cells derived from the breast, such as BT483, Hs578T, HTB26, BT20 and T47D. Normal mammary gland cell lines such as, for
35 example, CRL7030 and Hs578Bst, may also be used provided that a Di12 gene product is produced. Recombinant expression of the Di12 gene in these cells can be achieved by methods

described in Section 5.2. In these assays, cells producing functional D112 gene products are exposed to a test compound for an interval sufficient for the compound to modulate the activity of the D112 gene product. The activity of D112 gene product can be measured directly or indirectly through the detection or measurement of D112-dependent cellular processes. As a control, a cell not producing the D112 gene product may be used for comparisons. Depending on the cellular process, any techniques known in the art may be applied to detect or measure it.

5.6 METHODS FOR TREATMENT OF BREAST CANCER

Described below are methods and compositions for treating breast cancer using the D112 gene or gene product as a therapeutic target. The outcome of a treatment is to at least produce in a treated subject a healthful benefit, which in the case of breast cancer, includes but is not limited to remission of the cancer, palliation of the symptoms of the cancer, control of metastatic spread of the cancer.

All such methods comprise methods which modulate D112 gene activity and/or expression which in turn modulate the phenotype of the treated cell.

As discussed, above, successful treatment of breast cancer can be brought about by techniques which serve to decrease D112 activity. Activity can be decreased by, for example, directly decreasing D112 gene product activity and/or by decreasing the level of D112 gene expression.

For example, compounds such as those identified through assays described, above, in Section 5.5, above, which decrease D112 activity can be used in accordance with the invention to treat breast cancer. As discussed in Section 5.5, above, such molecules can include, but are not limited to peptides, including soluble peptides, and small organic or inorganic molecules, and can be referred to as D112 antagonists. Techniques for the determination of effective doses and administration of such compounds are described, below, in Section 5.7.

Further, antisense and ribozyme molecules which inhibit D112 gene expression can also be used in accordance with the invention to reduce the level of D112 gene expression, thus effectively reducing the level of D112 gene product present, 5 thereby decreasing the level of D112 activity. Still further, triple helix molecules can be utilized in reducing the level of D112 gene activity. Such molecules can be designed to reduce or inhibit either wild type, or if appropriate, mutant target gene activity. Techniques for the 10 production and use of such molecules are well known to those of skill in the art.

Any technique which serves to selectively administer nucleic acid molecules to a cell population of interest can be used, for example, by using a delivery 15 complex. Such a delivery complex can comprise an appropriate nucleic acid molecule and a targeting means. Such targeting means can comprise, for example, sterols, lipids, viruses or target cell specific binding agents. Viral vectors that can be used with recombinant viruses include, but are not limited 20 to adenovirus, adeno-associated virus, herpes simplex virus, vaccinia virus, and retrovirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes.

5.6.1 ANTISENSE MOLECULES

25 The use of antisense molecules as inhibitors of gene expression is a specific, genetically based therapeutic approach (for a review, see Stein, in Ch. 69, Section 5 "Cancer: Principle and Practice of Oncology", 4th ed., ed. by DeVita et al., J.B. Lippincott, Philadelphia 1993). The 30 present invention provides the therapeutic or prophylactic use of nucleic acids of at least six nucleotides that are antisense to a gene or cDNA encoding D112 or a portion thereof. An "antisense" D112 nucleic acid as used herein 35 refers to a nucleic acid capable of hybridizing to a portion of a D112 RNA (preferably mRNA) by virtue of some sequence complementarity. The invention further provides pharmaceutical compositions comprising an effective amount of

the Di12 antisense nucleic acids of the invention in a pharmaceutically acceptable carrier, as described *infra*.

In another embodiment, the invention is directed to methods for inhibiting the expression of a Di12 nucleic acid
5 sequence in a mammalian cell in vitro or in vivo comprising providing the cell with an effective amount of a composition comprising an Di12 antisense nucleic acid of the invention.

The antisense nucleic acid of the invention may be complementary to a coding and/or noncoding region of a Di12
10 mRNA. The antisense molecules will bind to the complementary Di12 gene mRNA transcripts and reduce or prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient
15 complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity
20 and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard
25 procedures to determine the melting point of the hybridized complex.

Nucleic acid molecules that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most
30 efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have recently shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, Nature
372:333-335. Thus, oligonucleotides complementary to either
35 the 5'- or 3'- non-translated, non-coding regions of the Di12 gene, as shown, for example, in Fig. 1, could be used in

an antisense approach to inhibit translation of endogenous D112 gene mRNA.

Nucleic acid molecules complementary to the 5' untranslated region of the mRNA should include the complement 5 of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'- , 3'- or coding region of target or pathway gene mRNA, 10 antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 15 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies 20 utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is 25 envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the 30 oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single- 35 stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule,

hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, 5 Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. 10 (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, 15 hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 20 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 25 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, 30 uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) 35 uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including

but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

While antisense nucleotides complementary to the D112 coding region could be used, those complementary to the transcribed untranslated region are most preferred. For example, antisense oligonucleotides having the following sequence can be utilized in accordance with the invention:

- a) 5'-CATGGCTACCATAGCTT-3' which is complementary to nucleotides -14 to +3 in Figure 1B.
- b) 5'-CATGGCTACCATAGCTTTCGCAGC-3' which is complementary to nucleotides -21 to +3 in Figure 1B.

- 5 c) 5'-CATGGCTACCATAGCTTTTCGCAGCAGCACCA-3' which is complementary to nucleotides -28 to +3 in Figure 1B.
- d) 5'-CATGGCTACCATAGCTTTTCGCAGCAGCACCAGCGCTTA-3' which is complementary to nucleotides -35 to +3 in Figure 1B.
- 10 e) 5'-AGCCATGGCTACCATAGCTTTTCGCAGCAGCACCA-3' which is complementary to nucleotides -28 to +6 in Figure 1B.
- f) 5'-GGCTACCATAGCTTTTCGCAGCAGCACCAGCGCTTA-3' which is complementary to nucleotides -35 to -1 in Figure 1B.
- g) 5'-TTTCGCAGCAGCACCA-3' which is complementary to nucleotides -28 to -13 in Figure 1B.

15 The antisense molecules should be delivered to cells which express the Di12 gene *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

20 However, it is often difficult to achieve intracellular concentrations of the antisense sufficient to suppress translation of endogenous mRNAs. Therefore a preferred approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous Di12 gene transcripts and thereby prevent translation of the Di12 gene mRNA. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as

long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art, and described in Section 5.6.4. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue.

5.6.2 RIBOZYME MOLECULES

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA (For a review see, for example Rossi, J., 1994, Current Biology 4:469-471). The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by a endonucleolytic cleavage. The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see U.S. Pat. No. 5,093,246, which is incorporated by reference herein in its entirety. As such, within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic

cleavage of RNA sequences encoding target gene proteins.

Ribozyme molecules designed to catalytically cleave Di12 gene mRNA transcripts can also be used to prevent translation of Di12 gene mRNA and expression of target or pathway gene.

- 5 (See, e.g., PCT International Publication WO90/11364, published October 4, 1990; Sarver et al., 1990, Science 247:1222-1225). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy Di12 gene mRNAs, the use of hammerhead ribozymes is preferred.
- 10 Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well
- 15 known in the art and is described more fully in Haseloff and Gerlach, 1988, Nature, 334:585-591. Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the Di12 gene mRNA; i.e., to increase efficiency and minimize the intracellular
- 20 accumulation of non-functional mRNA transcripts.

For example, hammerhead ribozymes having the following sequences can be utilized in accordance with the invention:

- a) 5'-CATCAAAGCNGNNNNNNCNGAGNAGUCGGCTAC-3' which will
25 cleave human Di12 mRNA between nucleotides -1 and +1 in Figure 1B.
- b) 5'-ACCCAAAGCNGNNNNNNCNGAGNAGUCTTTGTT-3' which will
cleave human Di12 mRNA between nucleotides -54 and -55 in Figure 1B.
- c) 5'-TCGCAAAGCNGNNNNNNCNGAGNAGUCCAGCAC-3' which will
30 cleave human Di12 mRNA between nucleotides -20 and -21 in Figure 1B.
- d) 5'-TACCAAAGCNGNNNNNNCNGAGNAGUCAGCTTT-3' which will
cleave human Di12 mRNA between nucleotides -9 and -10 in Figure 1B.

- 35 The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in Tetrahymena Thermophila

(known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al., 1984, Science, 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et al., 1986, Nature, 324:429-5 433; published International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, Cell, 47:207-216). The Cech-type ribozymes have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place.

10 The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences that are present in an D112 gene.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g. for improved 15 stability, targeting, etc.) and should be delivered to cells which express the D112 gene *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce 20 sufficient quantities of the ribozyme to destroy endogenous D112 gene messages and inhibit translation. Because ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Anti-sense RNA and DNA, ribozyme, and triple helix 25 molecules of the invention can be prepared by any method known in the art for the synthesis of DNA and RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite 30 chemical synthesis. Alternatively, RNA molecules can be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as 35 the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively

or inducibly, depending on the promoter used, can be introduced stably into cell lines.

Various well-known modifications to the DNA molecules can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of ribo- or deoxy- nucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

5.6.3 THERAPEUTIC ANTIBODIES

Antibodies exhibiting capability to downregulate Di12 gene product activity can be utilized to treat breast cancer. Such antibodies can be generated using standard techniques described in Section 5.3, above, against full length wild type or mutant Di12 proteins, or against peptides corresponding to portions of the proteins. The antibodies include but are not limited to polyclonal, monoclonal, Fab fragments, single chain antibodies, chimeric antibodies, and the like.

Because Di12 is an intracellular protein, it is preferred that internalizing antibodies be used. However, lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region which binds to the Di12 gene product epitope into cells. Where fragments of the antibody are used, the smallest inhibitory fragment which binds to the Di12 protein's binding domain is preferred. For example, peptides having an amino acid sequence corresponding to the domain of the variable region of the antibody that binds to the Di12 protein can be used. Such peptides can be synthesized chemically or produced via recombinant DNA technology using methods well known in the art (e.g., see Creighton, 1983, supra; and Sambrook et al., 1989, above). Alternatively, single chain antibodies, such as neutralizing antibodies, which bind to intracellular epitopes can also be administered. Such single chain antibodies can be

administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population by utilizing, for example, techniques such as those described in Marasco et al. (Marasco, W. et al., 1993, 5 Proc. Natl. Acad. Sci. USA 90:7889-7893).

5.6.4 GENE THERAPY

Gene therapy refers to treatment or prevention of cancer performed by the administration of a nucleic acid to a 10 subject who has cancer or in whom prevention or inhibition of cancer is desirable. In this embodiment of the invention, the therapeutic nucleic acid produces intracellularly an antisense nucleic acid molecules that mediates a therapeutic effect by inhibiting Dil2 expression. In another embodiment, 15 nucleic acids comprising a sequence encoding a dominant negative mutant Dil2 protein or non-functional fragment or derivative thereof, are administered to inhibit Dil2 function by interfering with the interactions of Dil2 and with other molecules in the cell.

20 For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. 25 Biochem. 62:191-217; May, 1993, TIBTECH 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and 30 Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds.), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.

In one aspect, the therapeutic nucleic acid comprises a Dil2 nucleic acid that is part of an expression vector that 35 expresses a dominant non-functional Dil2 protein or fragment or chimeric protein thereof in cancer cells. The function of Dil2 is thought to be mediated by protein-protein

interactions. Therefore, Di12 mutants that are defective in function but effective in binding to its interacting partner can be used as a dominant negative mutant to compete with the wild type Di12. Dominant non-functional Di12 can be
5 engineered for expression in cancer cells that inappropriately overexpress Di12.

In a preferred aspect, the therapeutic nucleic acid comprises an antisense Di12 nucleic acid that is part of an expression vector that produces the antisense molecule in a
10 suitable host. In particular, such a nucleic acid has a promoter operably linked to the antisense Di12 sequence, said promoter being inducible or constitutive, and, optionally, tissue-specific.

In another particular embodiment, a nucleic acid
15 molecule is used in which the antisense Di12 sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antisense Di12 nucleic acid (Koller and Smithies, 1989, Proc.
20 Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).

Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector or a
25 delivery complex, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid is directly
30 administered in vivo, where it is expressed to produce the antisense nucleic acid molecule or encoded non-functional Di12 gene product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and
35 administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see U.S. Patent No. 4,980,286), or by direct

injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in biopolymers (e.g., poly- β -1- \rightarrow 4-N-
5 acetylglucosamine polysaccharide; see U.S. Patent No. 5,635,493), encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis
10 (see e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the
15 nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180 dated April 16, 1992 (Wu et al.); WO 92/22635 dated December 23, 1992 (Wilson et al.); WO92/20316 dated November 26, 1992 (Findeis et al.);
20 WO93/14188 dated July 22, 1993 (Clarke et al.), WO 93/20221 dated October 14, 1993 (Young)). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad.
25 Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).

In a specific embodiment, a viral vector that contains the antisense D12 nucleic acid is used. For example, a retroviral vector can be used (see Miller et al., 1993, Meth.
30 Enzymol. 217:581-599). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The antisense D12 nucleic acid to be used in gene therapy is cloned into the vector, which
35 facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., 1994, Biotherapy 6:291-302, which describes the use of a retroviral

vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., 1994, 5 J. Clin. Invest. 93:644-651; Kiem et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.

Adenoviruses are other viral vectors that can be used in 10 gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, 15 endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499-503 present a review of adenovirus-based gene therapy. Bout et al., 1994, Human Gene Therapy 5:3-10 20 demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., 1991, Science 252:431-434; Rosenfeld et al., 1992, Cell 68:143-155; and Mastrangeli et 25 al., 1993, J. Clin. Invest. 91:225-234. Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., 1993, Proc. Soc. Exp. Biol. Med. 204:289-300).

The form and amount of therapeutic nucleic acid envisioned for use depends on the severity of the cancer, 30 desired effect, patient state, etc., and can be determined by one skilled in the art.

Endogenous *D12* gene expression can also be reduced by inactivating or "knocking out" the gene or its promoter using targeted homologous recombination. (E.g., see Smithies et 35 al., 1985, Nature 317:230-234; Thomas & Capecchi, 1987, Cell 51:503-512; Thompson et al., 1989 Cell 5:313-321; each of which is incorporated by reference herein in its entirety).

For example, a mutant, non-functional D112 gene (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous D112 gene (either the coding regions or regulatory regions of the D112 gene) can be used, with or
5 without a selectable marker and/or a negative selectable marker, to transfect cells that express D112 gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the D112 gene. Such approaches are particularly suited where modifications
10 to ES (embryonic stem) cells can be used to generate animal offspring with an inactive D112 gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, supra). Such techniques can also be utilized to generate animal models of breast cancer. It should be noted that this approach can be adapted for use
15 in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors, e.g., herpes virus vectors.

Alternatively, endogenous D112 gene expression can be
20 reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the D112 gene (i.e., the D112 gene promoter and/or enhancers) to form triple helical structures that prevent transcription of the D112 gene in target cells in the body. (See generally,
25 Helene, C. 1991, Anticancer Drug Des., 6(6):569-84; Helene, C., et al., 1992, Ann, N.Y. Acad. Sci., 660:27-36; and Maher, L.J., 1992, Bioassays 14(12):807-15).

5.7 PHARMACEUTICAL PREPARATIONS AND METHODS OF ADMINISTRATION

30

The compounds and nucleic acid sequences described herein can be administered to a patient at therapeutically effective doses to treat breast cancer. A therapeutically effective dose refers to that amount of a compound sufficient
35 to result in a healthful benefit in the treated subject.

5.7.1 EFFECTIVE DOSE

Toxicity and therapeutic efficacy of compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

5.7.2 FORMULATIONS AND USE

Pharmaceutical compositions for use in accordance with the present invention can be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

Thus, the compounds and their physiologically acceptable salts and solvents can be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

- 5 For oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or
- 10 hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
- 15 The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid
- 20 preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily
- 25 esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- 30 Preparations for oral administration can be suitably formulated to give controlled release of the active compound.
- For buccal administration the compositions can take the form of tablets or lozenges formulated in conventional manner.
- 35 For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized

packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit
5 can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

10 The compounds can be formulated for parenteral administration (i.e., intravenous or intramuscular) by injection, via, for example, bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose
15 containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form
20 for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa
25 butter or other glycerides.

In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly)
30 or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble
35 salt.

6. EXAMPLE: IDENTIFICATION OF A NOVEL GENE INVOLVED IN BREAST CANCER

This example describes the isolation and characterization of the Di12 gene. Two procedures:
5 subtractive hybridization cloning and differential display
PCR, were undertaken in order to isolate genes whose
expression is associated with breast cancer in various stages
of neoplastic development. The Di12 gene which is
overexpressed in cancer cells was selected for detailed
10 characterization.

6.1. MATERIALS AND METHODS

Cell Lines.

The human breast cancer cell lines (Hs578T, HTB26, BT20,
15 and T47D) and the normal breast cell lines Hs578Bst and
CRL7370 were obtained from the ATCC (Rockville, MD). The BT-
483 cell line was a gift from Prof. W.J. Gullick, Hammersmith
Hospital, London.

20 Tissue and Serum Samples.

Forty seven paraffin-embedded samples from breast
tissues were obtained from the Pathology Department at
Bradford Royal Infirmary (BRI). Ten fresh breast tissue
samples for RNA isolation were provided by the Surgical
25 Pathology Department at Women's College Hospital. All
patient samples received were graded for the presence of
malignancy by a pathologist to ensure characterization.
Sixty serum samples examined were randomly collected by BRI-
Biochemistry laboratory from breast cancer patients of the
30 cancer unit. Utilization of patient material and diagnostic
information was approved by the respective institutional
ethical review committees.

Northern Blotting and RT-PCR.

35 Total RNA from breast cancer cell lines or tissues was
isolated using the RNazol B method, and probed with cDNA
fragments as described previously (1995, Salesiotis et al.,

Cancer Letters, 91:47-54; 1996, Burger et al., *International Journal of Oncology*, 8:395-400). The RT-PCR amplifications were performed with D112 specific primers (sense: 5'-CGG CTG CTG GTG CTG ATT TG-3') and (antisense: 5'-CCA CGT GTC GCG TCA CCA AT-3') designed to generate a 415 bp product.

Subtractive Cloning.

The lambda ZAP II phagemid system (Stratagene, La Jolla CA) was used for the construction of directional libraries in opposite orientation using the EcoRI and XhoI sites. cDNA's were prepared from the 'normal' breast cell line Hs578Bst and the tumor cell line Hs578T as described (1990, Schweinfest et al., *Gene Anal Techn*, 7:64-70; 1995, Salesiotis et al., *Cancer Letters*, 91:47-54; 1996, Burger et al., *International Journal of Oncology*, 8:395-400).

Differential Display.

The differential display using the RNA prepared from normal (Hs578Bst) and breast cancer cell-lines (Hs578T, BT474, and BT20) using a kit from GenHunter Corp., (Brookline, MA) (1992, Liang et al., *Science*, 257:967-971). DNA from differentially displayed bands of interest were recovered, reamplified and cloned into pBS or TA cloning vectors (Stratagene or Invitrogen, San Diego, CA, respectively) and further characterized by DNA sequence analysis and Northern blotting.

6.2. RESULTS

30 6.2.1. CLONING OF BREAST CANCER-ASSOCIATED GENES

Using subtractive-hybridization techniques to identify genes linked to breast cancers, cDNA libraries enriched for breast cancer-associated cDNAs were generated. Single-stranded cDNA clones derived from a normal human breast cell-line, Hs578Bst, were subtracted using single-stranded cDNA clones of a breast carcinoma cell-line, Hs578T, derived from the adjacent malignant tissue of the same patient. A total

of 950 clones from the breast cancer enriched cDNA subtraction library were obtained and screened by Southern hybridization with the total cDNA from the Hs578T cDNA library. Clones positively expressed in tumor cDNAs and 5 negative in normal cDNAs were further analyzed by restriction mapping. The DNA sequence from eighty-one clones with inserts greater than 250 bp was determined and analyzed by FASTA and BLAST programs (GCG, LTW, Madison, WI and NIH, NILM, Basic Local Alignment Search Tool, respectively). 10 These analyses found 32 cDNAs to be novel and not previously identified, (e.g., as having no significant homology to genes listed in databases GenBank, EMBL)

A second strategy for obtaining differentially expressed genes in breast cancer cells was to clone PCR amplified cDNAs 15 reverse transcribed from RNAs derived from the normal (Hs578Bst) and tumor (Hs578T, BT474, and BT20) breast cell lines. The cDNAs differentially expressed from these human breast cell lines were cloned, and twenty-four of these were sequenced and compared to those in the databases; three of 20 them were found to be novel genes; having a differential pattern of expression in cell-lines and tissues. Among the known cDNAs, several of them include: c-fgr, E2A, tPA, osteonectin, and insulin-like growth factor binding protein, which have been previously reported to be involved in breast 25 and other cancers (1991, Abts et al., *Leuk. Res.*, 15:987-97; 1989, Murre et al., *Cell*, 56:777-783; 1991, Shimasaki et al., *J. Biol. Chem.*, 266:10646-10653).

6.2.2. FULL LENGTH CDNA CLONING AND PROTEIN SEQUENCE ANALYSIS OF Di12

30

The full-length Di12 cDNA (1363 bp) was cloned from a CEM cDNA library. The DNA sequence contains an open reading frame of 339 amino acids in which the first ATG, (G-C-C-A-T-G-G) is homologous to the Kozak consensus (A/G-X-X-A-T-G-G) 35 (1981, Kozak, M., *Nucleic Acids Res.*, 9:5233-5262); the protein translation start site (Figure 1B). Using the GCG UW MOTIFS program we found: four consensus (N-X-S/T) N-

glycosylation sites at positions 62, 65, 196, 277; six Ck-2 sites (consensus S/T-X-X-D/E) at positions 67, 137, 163, 189, 199, and 235; seven PKC sites (consensus S-X-K) at positions 7, 10, 100, 124, 165, 189, and 248; and various
5 myristoylation sites. The PEPLOT program predicts several hydrophobic regions in the Di12 protein, including a hydrophobic tail at the C-terminus. To confirm the open reading frame, the Di12 cDNA was subcloned into the pSG5 expression vector and was used in an *in vitro* coupled
10 transcription-translation system. As expected, a 35 kD protein was produced with the vector containing the Di12 insert (Fig. 2, Lane 1), but not with the control vector (pSG5) without the insert (data not shown). The 35 kD expressed product is also recognized by anti-Di12 antibodies
15 in immunoprecipitation assays (Figure 2, Lanes 3 and 4) and not by preimmune serum (Fig. 2, Lane 2).

6.2.3. EXPRESSION OF Di12 RNA

The Di12 gene was found to be expressed as a 1.35 kb RNA
20 in several breast cancer cell lines, with the highest levels observed in BT483 (Fig. 3A, lane 1), lower levels in Hs578T (Fig. 3C, lane 2), and very weak or no expression was observed in HTB26, BT-20 and T47D cell lines (Fig. 3A and C). Di12 expression was undetectable in the normal mammary gland
25 cell line CRL 7370 (Fig. 3A, lane 3), and was barely detectable in another normal breast cell line Hs578Bst (e.g., only after prolonged exposures using increased amounts of poly(A) RNA (data not shown). Di12 RNA was found to be expressed in various normal human (Fig. 3E) and rat (Fig. 3F)
30 tissues, including lung, kidney, pancreas, and heart, but it was expressed at low levels or not detectable in the brain, placenta, and liver. The similar tissue expression pattern of Di12 in rat and human tissues indicates that this gene is likely to be conserved between mammalian species and may have
35 similar function(s) as well.

7. EXAMPLE: DIAGNOSIS AND STAGING OF BREAST CANCER

This example illustrates the association of Di12 gene expression with breast cancer, and in particular infiltrating ductal carcinomas.

5

7.1. MATERIALS AND METHODS

Di12 Antibodies.

Antibodies were raised in rabbits against the N-terminal 12 amino acid synthetic peptide: MARDGASIKTIK (cf. Figure 10 2).

Immunohistochemistry.

Immunohistochemical localization of Di12 protein was examined in two paraffin-embedded breast cancer cell lines 15 and various primary tissue samples including thirty three malignant IDCs, three DCIS, five LCIS and six normal breast samples from reduction mammoplasties with the HistoStain™ SP Kit (rabbit, Zymed, San Francisco, CA) as described (1995, Soubeyran et al., *Breast Cancer Res. Treat.*, 34:119-128). 20 The Elston-modified Bloom and Richardson method was used for histological grading of breast tumors (1991, Elston et al., *Histopathol.*, 19:403-410).

ELISA Assay.

25 Detection of Di12 gene product with Di12 antibody in patient sera was performed using the ELISA procedure from the ExtrAvidin Peroxidase Staining Kit (anti-human, Sigma, Poole, Dorset, UK). Specific binding was detected with a biotin/streptavidin-peroxidase system 2,2'-azino-bis-(3- 30 ethylbenzthioazline-6-sulfuric acid) as substrate, the absorption (at 405 nm) of positive reactions was compared to known Di12 antibody concentrations.

7.2. RESULTS

35 In order to determine if Di12 is differentially expressed in different types of breast cancer or if it is stage related, we examined fresh tissue samples obtained from

normal breast, fibroadenomas and fibrocystic disease with non-proliferative and proliferative changes both with or without atypia, as well as ductal carcinomas *in situ* and infiltrating ductal carcinomas were analyzed by
5 immunohistochemistry, ELISA, and RTPCR.

7.2.1. IMMUNOHISTOCHEMICAL ANALYSIS

As shown above, Northern blot analysis indicated that the breast cancer cell lines BT483 and Hs578T produce high
10 and low levels of D112 RNA respectively (Fig. 3A-C).

Paraffin embedded sections of these cells were therefore included as positive and negative controls.

A total of forty-seven paraffin embedded normal and primary malignant breast tissues were screened for tissue
15 distribution of D112 gene product. In particular, six normal breast tissues from breast reductions, 5 lobular carcinomas *in situ*, 3 ductal carcinomas *in situ* and 33 IDCs of various grades and stages of disease progression were examined. A representative panel of immunostained sections from cell line
20 and tissue samples is shown (Figure 4A-H). Specific, strong D112 staining was seen in cytoplasm of IDCs with a slight increase in perinuclear regions of less well differentiated cells with poor prognosis (Fig. 4E-G). In contrast, normal breast tissue (Fig. 4H) showed no D112-specific staining. As
25 expected, BT 483 cells showed the strongest D112 protein staining (Figure 4A and D); whereas Hs578T, with low levels of D112 gene expression, showed weaker staining with D112 antibody (Fig. 4C).

30

7.2.2. RT-PCR ANALYSIS

In order to complement the protein expression data and confirm if D112 is differentially expressed in different types of breast cancer or is stage related, fresh tissue
35 samples from normal breast, fibroadenomas and fibrocystic disease with non-proliferative and proliferative changes and those with or without atypia, as well as ductal carcinomas *in situ* and infiltrating ductal carcinomas were analyzed by

reverse transcription-polymerase chain reaction (RT-PCR). Our results show that Di12 expression is associated with more than eighty percent of the confirmed IDC specimens and was absent in non-malignant samples (Figure 5). Interestingly, the only, Di12-negative IDC specimen was in fact described histologically as having extensive tissue necrosis with a single intraductal papilloma localized distal from the tumor site. RT-PCR, although not quantitative, did generate bands with different intensities, suggesting varying levels of Di12 gene expression between samples.

7.2.3. IMMUNOASSAY

To investigate whether Di12 gene product might be useful as a serological marker for infiltrating ductal carcinomas, sera from sixty patients were examined for the presence of Di12 gene product using specific Di12 antibody. An enzyme linked immunosorbent assay was developed to detect circulating Di12 protein. Thirty-seven out of sixty breast cancer sera examined showed elevated levels for the Di12 gene product. Background levels for ELISA-Di12 was determined as 35 ng/ml in the assays using standardized quantities of Di12 antibody coated plates. The Di12 ELISA positive samples were nearly all associated with invasive ductal carcinomas (IDC), with higher levels noted in sera from patients having lymph node or distant metastases (Figure 6). Significantly, sera from three ovarian cancer patients, as well as all three patients with benign breast disease, were negative for Di12 product by this assay. The Di12 serum protein determined by ELISA appeared to be related to grade and stage of disease, with DCIS having the lowest levels and IDC accompanied with metastatic disease being the highest levels as depicted in Figure 6.

7.3. DISCUSSION

The evaluation of Di12 gene expression in breast carcinomas as described in sections 7.2.1 and 7.2.2 showed that it is predominantly associated with tumors of the

infiltrating ductal type, but not with ductal carcinoma in situ, benign fibroadenomas, or normal breast tissue obtained from reduction mammoplasty. Moreover the Di12 antibody data as described in 7.2.3 were in close agreement with RT-PCR and
5 Northern blot data obtained from cell lines and primary tissues. By both Northern blot and immunohistochemistry, there were high levels of Di12 expression found in BT483 and Hs 578T breast cancer cell lines. Similarly a good correlation in Di12 gene expression by RT-PCR, was observed
10 with the positive staining of Di12 protein by immunoperoxidase technique in primary tissues, further confirming the sensitivity and accuracy of each of the methods employed. In general homogeneous cytoplasmic distribution of Di12 specific protein was seen throughout
15 infiltrating pleomorphic cells and malignant cells invading vascular spaces, but not in normal cells. Collectively these results suggest that Di12 gene expression is indeed associated with advanced and aggressive disease, particularly IDCs.

20 Moreover, random measurement of serum Di12 protein levels indicates that gene expression is significantly increased if IDCs are accompanied by regional lymph node involvement, and most highly elevated if distant metastases are present. Since the predicted Di12 protein lacks a signal
25 sequence, the observed serological circulation of Di12 protein, could be linked to the malignant invasiveness of IDC associated disease. The data derived from clinical specimen shows that the Di12 gene product is a useful prognostic marker for invasive ductal carcinomas. Since the IDC
30 constitutes more than 70 percent of routine clinical specimens, a positive marker for IDC could be useful in the diagnosis and management of patients after primary resection and could also identify, at an early stage, those women who might benefit from a more aggressive therapeutic protocol.

35

8. DEPOSIT OF MICROORGANISMS

E. coli strain DH5, containing a clone of a cDNA encoding Di12, pBS-Di12, was deposited on March 20, 1998 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and bears the ATCC accession number _____.

10 The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of
15 the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

20

25

30

35

IN THE CLAIMS:

1. An isolated nucleic acid molecule comprising:
 - 5 (a) nucleotide sequence that encodes a polypeptide having the amino acid sequence of Figure 1A;
 - (b) the complement of the nucleotide sequence
10 of (a); and
 - (c) a nucleic acid molecule capable of hybridizing to and which is at least 80% identical to a nucleic acid molecule of
15 (a) or (b).
2. An isolated nucleic acid molecule comprising a nucleotide sequence that hybridize to the nucleic acid of
20 Claim 1 and encodes a naturally occurring Di12 polypeptide.
3. An isolated nucleic acid molecule comprising the
25 nucleotide sequence of Figure 1B.
4. An isolated nucleic acid molecule of claim 1, which
is genomic DNA.
- 30 5. An isolated nucleic acid molecule of Claim 1, which
is cDNA.
- 35 6. An isolated nucleic acid molecule of Claim 1, which
is RNA.

7. An isolated nucleic acid molecule of claim 1, which hybridizes to at least 6 consecutive nucleotides of the Di12 gene as set forth in Figure 1B.

5

8. An isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes to the nucleic acid of Claim 1 and encodes a polypeptide with an activity of a Di12
10 protein, or a fragment thereof, linked uninterrupted by stop codons to a nucleotide sequence that encodes a heterologous protein or peptide.

15

9. A nucleic acid molecule comprising a nucleotide sequence encoding (a) a deletion mutant of Di12; or (b) the complement of the nucleotide sequence.

20

10. An isolated nucleic acid molecule of claim 7, further comprising a label.

25

11. A recombinant vector containing the nucleotide sequence of Claim 1, 2, 3, 8, or 9.

30

12. An expression vector containing the nucleotide
sequence of Claim 1, 2, 3, 8, or 9 operatively associated
with a regulatory nucleotide sequence containing
transcriptional and translational regulatory information that
controls expression of the nucleotide sequence in a host
35 cell.

13. A genetically engineered host cell containing the nucleotide sequence of Claim 1, 2, 3, 8, or 9.

5 14. A genetically engineered host cell containing the nucleotide sequence of Claim 1, 2, 3, 8, or 9 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that
10 controls expression of the nucleotide sequence in a host cell.

15 15. The genetically engineered host cell of Claim 14 in which the host cell is prokaryotic.

20 16. The genetically engineered host cell of Claim 14 in which the host cell is eukaryotic.

25 17. The microorganism deposit of E. coli DH5 containing the plasmid pBS-Di12 bearing American Type Culture Collection Deposit Accession No. _____.

30 18. A transgenic animal comprising the nucleic acid of claim 1.

35 19. A transgenic animal in which expression of a genomic sequence encoding a functional Di12 polypeptide is prevented or suppressed.

20. A delivery complex comprising a nucleic acid molecule of claim 1 or 2 and a targeting means.

5 21. The delivery complex of claim 20, wherein the targeting means is selected from the group consisting of: a sterol, a lipid, a virus or a target cell specific binding agent.

10

22. A delivery complex comprising an expression vector of Claim 12 and a targeting means.

15

23. A delivery complex of Claim 22, wherein the targeting means is selected from the group consisting of: a sterol, a lipid, a virus or a target cell specific binding agent.

20

24. A delivery complex of Claim 22, wherein the targeting means is selected from the group consisting of a recombinant adenovirus, a recombinant adeno-associated virus, a recombinant retrovirus, a recombinant herpes simplex virus, and a recombinant vaccinia virus.

30

25. A method for detecting the presence of a nucleic acid molecule of claim 1, in a sample comprising:

35

(a) contacting the sample with a nucleic acid probe capable of specifically hybridizing to at least a portion of the nucleic acid molecule of claim 1 under hybridizing conditions; and

(b) measuring the hybridization of the probe to the nucleic acid of the sample, thereby detecting the presence of the nucleic acid
5 sequence.

26. A method for detecting the presence of the nucleic acid molecule of claim 1, in a sample comprising:

10 (a) contacting the sample with nucleic acid primers capable of specifically binding to at least a portion of the nucleic acid molecule of a claim 1 under hybridizing conditions;

15 (b) selectively amplifying at least a portion of the nucleic acid molecule of claim 1 and

(c) detecting the amplified nucleic acid of the
20 cell,
thereby detecting the presence of the nucleic acid molecule.

25 27. A test kit for detecting and/or quantitating a wild type or mutant D112 nucleic acid molecule in a sample, comprising:

(a) contacting the sample with a nucleic acid
30 molecule of claim 10; and

(b) detecting and/or quantitating the label as an indication of the presence or absence and/or amount of a wildtype or mutant D112 nucleic acid.
35

28. A method of making a Di12 polypeptide comprising the steps of:

(a) culturing the cell of claim 15 in an appropriate culture medium to produce Di12 polypeptide; and

(b) isolating the Di12 polypeptide.

29. A method of making a Di12 polypeptide comprising the steps of:

(a) culturing the cell of claim 16 in an appropriate culture medium to produce Di12 polypeptide; and

(b) isolating the Di12 polypeptide.

30. An isolated mammalian soluble Di12 polypeptide that is present in a body fluid.

31. An isolated polypeptide encoded by the nucleic acid molecule of claim 1.

32. An isolated polypeptide having the amino acid sequence of Figure 1A.

30

33. A polypeptide of claim 31, which is at least 90% identical to the polypeptide as set forth in Figure 1A.

35

34. A fusion protein comprising a polypeptide of claim 31 and a second polypeptide which is a detectable label or a matrix binding domain.

5

35. A pharmaceutical preparation comprising a therapeutically effective amount of the polypeptide of claim 33 and a pharmaceutically acceptable carrier.

10

36. An antibody to the polypeptide of claim 30, 31, 33 or 34.

15

37. The antibody of claim 36 which is monoclonal.

38. An antibody preparation, which is specifically reactive with an epitope of a D112 polypeptide, and which comprises a fragment of the antibody selected from the group consisting of F(ab)'₂, Fab, and Fv fragment.

20

39. A pharmaceutical preparation comprising a therapeutically effective amount of an antibody preparation of claim 36 and a pharmaceutically acceptable carrier.

25

40. A method for detecting or measuring a polypeptide of claim 30, 31 or 33 in a sample comprising:

30

(a) contacting the sample with an antibody to D112 gene product under conditions which allow immunospecific binding; and

35

(b) detecting or measuring the immunospecific binding of the antibody to the sample, thereby determining the presence of or measuring the
5 quantity of the polypeptide in the sample.

41. A method for diagnosing breast cancer in a human subject comprising detecting or measuring a D112 gene product
10 in a body fluid from the subject, in which elevated levels of the D112 gene product indicate the existence of breast cancer.

15 42. The method of claim 41 wherein the elevated levels of the D112 gene product indicate the existence of breast cancer as opposed to a benign disease of the breast.

20 43. The method of claim 41 wherein the breast cancer is infiltrative ductal carcinoma.

25 44. A method for staging a breast cancer in a human subject comprising detecting or measuring a D112 gene product in the subject, in which elevated levels of the D112 gene product indicate an advanced stage of breast cancer.

30 45. The method of claim 44 wherein the breast cancer involves regional lymph nodes.

35 46. The method of claim 44 wherein the breast cancer involves metastases.

47. A method for monitoring the effect of a therapeutic treatment on a human subject with breast cancer comprising measuring Di12 gene product in the subject in which elevated
5 levels of Di12 gene product indicate a poor response to the treatment.

48. The method of claim 41, 42, 43, 44, 45, 46, or 47
10 wherein the Di12 gene product is a soluble Di12 gene product present in a body fluid obtained from the subject.

49. The method of claim 48 wherein the body fluid is
15 serum.

50. A method for identifying compounds that
20 modulate Di12 gene expression, comprising:
(a) contacting a test compound with a cell or cell lysate containing a reporter gene operatively associated with a Di12 regulatory element; and
25 (b) detecting expression of the reporter gene product.

51. A method for identifying compounds that modulate
30 Di12 gene expression comprising:
(a) contacting a test compound with a cell or cell lysate containing Di12 transcripts; and
(b) detecting the translation of the Di12
35 transcript.

52. A method for the treatment of breast cancer comprising administering an effective amount of a compound that decreases expression of Di12.

5

53. A method for the treatment of breast cancer comprises administering an effective amount of a compound that antagonizes the activity of Di12.

10

54. A method for the treatment of breast cancer in a subject with cancer comprising administering to a subject an effective amount of a nucleic acid molecule encoding an
15 antisense or ribozyme molecule that targets Di12 transcripts, and interferes with translation of Di12 transcripts.

20

55. A method for the treatment of breast cancer in a subject with cancer comprising administering to a subject an effective amount of a nucleic acid molecule that forms a triple helix with the promoter of the Di12 gene, and inhibits
25 transcription of the Di12 gene.

30

56. The method of claim 52, 53, 54, or 55 wherein the breast cancer is infiltrative ductal carcinoma.

57. The method of claim 56 wherein the breast cancer involves metastases.

35

1/11

1 MARDGASIKTIKSEFPAIAQAATAAGADLQQTASVVQQSMNIWGDSIQSPQRAAAVLTQT
61 ANLSNASIEDMQQALATIGGTAHNAGIDMQTTSTAIGLLTNRGFSAAQASQDLNHALLM
121 QAPSEKGAGVMHNLGLSNTDAQGNMKPLPKILNEIGDATRGMTSSDKAAALKAMFGTAGM
181 AAILPLMDSVKDKTGNATTSWEAFTKEMDKASGSTQTATNFLKDQANEMQKNLGSKIEQV
241 GGNWEALSNKAMAGSSGVTGAFLDMTNSALSWAGSSSSMAQFSRQMLGLAPAIGPVVTA
301 LGGFITNAGKITGLVKMGSAVIGAGKGMVSFVAFFFFV

FIG. 1A

2/11

1 ggggtggagacttccaagcgtcacttaaccaagccgcagtcatecgtgggtggtacatcaaa
61 agacattaacggacttgctgacgtagccaacaaaatgggtgctgacctgcctttaagcgc
121 tgggtgctgctgcgaangetatggtagccatggctcgtgacggagcgtctatcaagacaat
181 taaatcagagttcccagctattgcgcaagctgcaacggctgctgggtgctgatttcagca
241 aacagcgtcagttgttcaacaatcgaatgaacatctgggggtgtagtattcaagcccaca
301 acgtgctgctgctgtattaacgcaaaactgctaacctatccaacgcctcaatcgaagatat
361 gcaacaggcttttagctactatcggtggtagcgacacacaacgctgggtatcgacatgcaaac
421 aacgtctaccgctatcggttacttactaaccgtgggttcagtgtgcacaagcgtcaca
481 agacttgaacctgctttgttgcctatgcaagctccaagtgaanaaggagctgggtgat
541 gcacaatctcggtttgtctatgacagacgcacaaggaaacatgaagccgttaccaaaaat
601 ttggaatgaaattgggtgacgcgacacgtgggatgactagttctgataaagcagcagcgtt
661 gaaggctatgtttgggtactgctgggtatggctgctattcttcttggatggatagtgtaa
721 ggataagactggtaafgctaccacaagttgggaagctttcaccaagaaatggataaagc
781 gtcaggaagtagcgaacagctacaaaacttcctaaaagatcaagcaaacgaaatgcagaa
841 aaacttgggttctaagatcgaaacagtcgggtggtaactgggaagcattagcaacaaggc
901 tatggctggatcttctgggtgctcactgggtcggttccttgacatgacaaatagcgcattaag
961 ttgggtggttctagtaatagttcaatggcacagttttcacgtcaaatgcttgggttagc
1021 accagctatcgggccagttgttactgctttgggtggatttattaccaacgctgggaagat
1081 tactggactggtaaaaagggtatgggttcagcagttattgggtgctggtaagggaaatggttag
1141 tttgttgcttttttttcttggtaaacagtgaaataactaaagtgttagtggt
1201 tggattaaaagaanaacttattaggcaagaacaggtaatgtagttatccatgactacttta
1261 accatgcagactaataatattctggagggtttatagctcggcaccttcacctttttcact
1321 ggtatttcatgtaaggcatcaaccactgtgaaaaaaaaaaaaaaaaaaaaa 1374

FIG. 1B

3/11




FIG. 2

4/11




FIG. 3A





FIG. 3B

5/11



1 2 3

FIG. 3C




FIG. 3D

6/11




FIG. 3E

7/11




FIG. 3F




FIG. 3G

8/11



FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D

9/11




FIG. 4E



FIG. 4F



FIG. 4G




FIG. 4H

10/11




FIG. 5

11/11




FIG. 6

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 80, lines 1-7 of the description *

A. IDENTIFICATION OF DEPOSIT *

Further deposits are identified on an additional sheet *

Name of depositary institution *

American Type Culture Collection

Address of depositary institution (including postal code and country) *

12301 Parklawn Drive
Rockville, MD 20852
US

Date of deposit * March 20, 1998 Accession Number * _____

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not all designated States)

D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☐ This sheet was received with the International application when filed (to be checked by the receiving Office)

(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau "

was

(Authorized Officer)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/05629

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/02; C12P 21/06; C07K 1/00, 14/00

US CL : 536/23.1; 435/69.1; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1; 435/69.1; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	BURGER, A. et al. A novel membrane protein associated with late stage breast cancer. Protein Engineering. 1997, Vol. 10 (Suppl.), page 80, 2nd column, see entire document.	9, 11-16, 28-30
Y, P	BURGER, A. M. et al. Breast cancer associate gene Di12 confers mammary tumor formation in nude mice. 89th Annual Meeting of the American Association for Cancer Research, Proceedings of the American Association for Cancer Research Annual Meeting. March 1998. Vol. 39, page 273, abstract 1868, see entire abstract.	9, 11-16, 28-30
X, P	BURGER, A. et al. Breast genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene. 22 January 1998, Vol. 16, pages 327-333, see entire document.	9, 11-16, 28-30



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 JUNE 1998

Date of mailing of the international search report

27 JUL 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LIN SUN-HOFFMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/05629

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-17, 25-27, drawn to an isolated nucleic acid molecule.

Group II, claim(s) 18-24, drawn to a transgenic animal.

Group III, claim(s) 28-35, drawn to a polypeptide.

Group IV, claim(s) 36-49, drawn to an antibody.

Group V, claim(s) 50-57, drawn to a method of screening a compound and a method of treatment.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is considered to be a nucleic acid molecule, while Group II is a transgenic animal, Group III is a polypeptide, Group IV is an antibody, and Group V is a method of screening a compound. Because the special technical feature of the Group I is not present in the other groups and because the special technical feature of Group I, II, III and IV are not present among them, unity of invention is lacking.